

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Universal healthcare coverage, cancer screening and potential barriers to accessing cancer care in Sub-Saharan Africa: The results and implications of a Cross-sectional Community Study in Rural South-West Nigeria

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040352
Article Type:	Original research
Date Submitted by the Author:	12-May-2020
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Universal healthcare coverage, cancer screening and potential barriers to accessing cancer care in Sub-Saharan Africa: The results and implications of a Cross-sectional Community Study in Rural South-West Nigeria

Sharma A. MD¹, Alatise O. I. MBChB², O'Connell K. MSc³, Gbenga O.S. MSc², Aderounmu A.A. MBChB², Samson. M.L. BSc³, Wuraola F. MBChB², Olasehinde O. MBChB, Kingham T.P MD¹, Du M. ScD³

¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; ²Obafemi Awolowo University, Ile-Ife, Nigeria; ³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

Acknowledgments: The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

Funding: This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's Center for Global Health to perform dedicated cancer research in the region. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Correspondence:

Avinash Sharma

Memorial Sloan Kettering Cancer Center

1275 York Avenue, C-886

New York, NY 10065

avinash.s.sharma@gmail.com

ne to declare Conflicts of Interest: None to declare

Author contributions:

1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

4. O.S. Gbenga

Author contributions: study organisation, data collection

5. A.A. Aderounmu

Author contributions: study organisation, data collection

6. M.L.Samson

Author contributions: study and questionnaire design

7. F. Wuraola

Author contributions: Manuscript revision

8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

10. **M. Du**

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

to beet terien only

ABSTRACT

Background/Aims: Cancer burden is predicted to double by 2030 in sub-Saharan Africa. Accordingly, access to healthcare services for cancer management has been made a priority in the region. In Nigeria, the National Cancer Control Plan aims to ensure greater than 50% cancer screening of eligible populations by 2022 for all Nigerians. This study sought to describe current healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria.

Methods: During April 2018, a cross-sectional study of community-based adults (>18 years) was conducted approximately 130 kilometers east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. A validated questionnaire was used to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

Results: A total of 346 individuals were enrolled; the median age was 52 years, and 75% of participants were female. Of the entire cohort, only 4% had medical insurance,. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent, with 1.5% of participants reporting having cervical cancer screening and 3.3% of participants >40 years having a mammogram. Colonoscopy screening in those >50 years was 5%. Cancer screening assessment was less frequent in those with less income and lower levels of education. Despite this, we observed that most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exist.

Conclusions: Despite expected increases in cancer cases, our data highlight a deficiency in cancer screening and lack of universal healthcare coverage within a community-based adult Nigerian population. Increasing financial risk protection, awareness, and targeted resource allocation may help expand access.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

Strengths and Limitations of the study:

- The study provided a contemporary perspective potential barriers to accessing medical and cancer care in rural South-West Nigeria. Recruitment and data collection performed by interviewers fluent in the local dialect who underwent a systematic and rigorous two-day training program.
- Questionnaire tailored to the local population and developed in collaboration with local clinicians, epidemiologists, and nutritionists. Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
- 5) Survey conducted at a single time (mid-week, during the day), which may have affected sample composition (e.g., more females than males).

pple con-

INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.¹⁻³ According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.^{4 5} In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.⁶⁻⁸ Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.⁹

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.^{7 10} In the region, out-of-pocket health expenditures are a major contributor to poverty ¹¹⁻¹³, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.¹⁴ However, uptake has been limited and restricted,¹⁵ and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.^{15 16}

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.¹⁷ The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.¹⁷⁻¹⁹ Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

BMJ Open

Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."²⁰ Despite this, the current state of cancer screening and barriers to care in this region (esp. rural areas) are not well-defined. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. In addition, with 50 percent of Nigeria's population living in rural areas²¹ we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria²² investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.^{6 19 20 23} Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

METHODS

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns Ijebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the

BMJ Open

main tertiary referral center in the region. The study was approved by the Obafemi Awolowo University institutional ethics review committee.

Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Based on the resource capacity of each town hall and the size of each community, enrolment was to be capped at a maximum of 300 participants at ljebu-Jesa and 100 at Ere-Jesa. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained research assistant. All research assistants underwent a two-day training program that involved education in the research aims, methodology, and ethics as well as interview techniques and the use of electronic tablets for recording data. The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication

BMJ Open

use, and environmental exposures. Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. The questionnaire, developed in collaboration with local clinicians, epidemiologists, and nutritionists, was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,²⁴ Nigeria General Household Survey,²⁵ World Health Organization-endorsed Global Physical Activity Questionnaire,²⁶ and the Nurses' Health Study questionnaire.²⁷⁻³⁰ Demographic and socioeconomic data collected from our study population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator ^{31 32} to assess external validity.

Statistical analysis

BMJ Open

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed. Enrolment was capped at this number to ensure complete surveys could be conducted for all individuals. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

Table 1: Demographic characteristics of the study group (n=346)

(n=268 ljebu-Jesa, n=68 Ere-Jesa)

Variable	n (%)
Median Age, years (range)	52 (18-100)
Sex	
Male	85 (24.6)
Female	261 (75.4)
Marital Status	
Single	27 (7.8)
Married	213 (61.6)
Other (Divorced/cohabiting)	106 (30.6)
Tribe	
Yoruba	332 (96.0)
Ibo	5 (1.4)

2	
3	
4	
5	
6	
7	
8	
9	
1	0
1	1
1	
1	
	4
	5
1	6
1	7
1	8
	9
	0
2	1
2	ו ר
2	
2	
	4
2	5
2	6
	7
	, 8
	9
	0
	1
3	
3	3
	4
	5
	6
с 2	7
3	
3	8
3	
4	0
4	
4	
4	
	4
4	
	6
4	7
4	8
4	9
	0
	1
5	
с 5	∠ ∽
	4
5	
5	
5	
	, 8
_	9
6	0

Delinian	Other	9 (2.6)
Religion	Christian	326 (94.2)
	Muslim	19 (5.5)
	Other	1 (0.3)
Education		
	No formal education	88 (25.4)
	Primary	92 (26.6)
	Secondary	92 (26.6)
	Vocational/Technical	45 (13.0)
	Higher	29 (8.4)
Occupation	-	
	Unemployed	30 (8.7)
	Civil servant	30 (8.7)
	Trader	123 (35.5)
	Farmer	35 (10.1)
	Self-employed	80 (23.1)
	Other	48 (13.9)
Number of Live Births (F	emales, n=242)	
	0	6 (2.5)
	1	15 (6.2)
	2	23 (9.5)
	3	28 (11.6)
	4	54 (22.3)
	5 or more	116 (47.9)

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian Demographic and Health Survey (**Table 2b**).³¹ Both groups had similar degrees of

education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,³² our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

		1
Variable		n (%)
Personal income (per mo	nth, in Naira)	
	<10,000	155 (44.8)
	10,000-49,999	139 (40.2)
	50,000-99,999	26 (7.5)
	100,000-249,999	16 (4.6)
	250,000-499,999	9 (2.6)
	≥500,000	1 (0.3)
Family income (per month	n, in Naira)	
	<10,000	117 (33.8)
	10,000-49,999	147 (42.5)
	50,000-99,999	38 (11.0)
	100,000-249,999	28 (8.1)
	250,000-499,999	11 (3.2)
	≥500,000	5 (1.4)
Type of dwelling		
	Own apartment	131 (37.9)
	Rent apartment	146 (42.2)
	Family house	67 (19.4)
	Other	2 (0.6)
Type of toilet		
	Water system	151 (43.6)
	Pit latrine	164 (47.4)
	Bush	23 (6.6)
	Bucket	7 (2.0)
	Other	1 (0.3)
Water source		
	Pipe borne/boreholes	185 (53.5)

Table 2a: Income and household conditions

	Well	146 (42.2)
	River	15 (4.3)
Appliances		
	Electricity	318 (91.9)
	Television	262 (75.7)
	Radio	251 (72.5)
	Refrigerator	154 (44.5)
	Air conditioner	8 (2.3)
	Generating set	99 (28.6)
	Personal computer	38 (11.0)
	None	18 (5.2)

Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

NDHS Urban	NDHS Rural	NDHS Total	Current study
(%)	(%)	(%)	(%)
0.7	0.2	0.4	10.7
4.6	0.5	2.3	21.1
47.6	8.7	25.5	31.8
5.3	1.6	3.2	2.3
37.9	83.3	63.7	34.1
83.6	34.4	55.6	91.9
16.3	65.4	44.2	8.1
0.1	0.2	0.2	0
77.7	61.3	68.3	72.5
73.2	28.2	47.6	75.7
32.5	7.5	18.3	44.5
12.7	18.3	18.3	0.9
27.0	31.2	31.2	15.0
14.4	8.7	8.7	12.1
NDHS	NDHS	Current	Current study
Female	Male	study	Male
(%)	(%)	Female	(%)
-	-	(%)	
37.8	21.2	28.7	15.3
17.3	16.7	26.8	25.9
35.8	47.7	28.0	22.4
	14.3	16.5	36.5
	Urban (%) 0.7 4.6 47.6 5.3 37.9 83.6 16.3 0.1 77.7 73.2 32.5 12.7 27.0 14.4 NDHS Female (%) 37.8 17.3	Urban (%)Rural (%)0.7 4.60.2 0.547.6 5.3 37.98.7 1.6 83.383.6 16.3 0.134.4 0.277.7 77.7 32.561.3 28.2 7.512.7 12.7 14.418.3 31.2 31.2 14.4NDHS Female (%)NDHS Male (%)37.8 17.321.2 16.7	Urban (%)Rural (%)Total (%) 0.7 4.6 0.2 0.5 0.4 2.3 47.6 5.3 37.9 8.7 83.3 25.5 3.2 63.7 83.6 16.3 0.1 34.4 0.2 55.6 44.2 0.2 77.7 77.7 61.3 28.2 7.5 68.3 47.6 18.3 31.2 31.2 31.2 12.7 14.4 18.3 8.7 18.3 31.2 8.7 NDHS Female (%)NDHS $Male$ (%)Current study Female (%) 37.8 17.3 21.2 16.7 28.7 26.8

Within the group surveyed, cancer screening/assessment activities were limited: 2% (4/267) of female participants had a previous cervical smear/assessment, and 3%

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

(6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was also infrequent.

Variable	n (%)
Cancer screening	
Cervical Cancer assessment	
(if female > 21, n = 261)	4 (1.5)
Previous mammogram (if female >40, n = 183)	6 (3.3)
Previous colonoscopy (if >50	0 (3.3)
years, n = 190)	9 (4.5)
Last primary health care physician	
visit	
<1 year ago	180 (52.0)
1-4 years ago	93 (26.9)
5-10 years ago	32 (9.2)
>10 years ago	41 (11.8)
Last time seen traditional healer	
Never	254 (73.4)
<2 years ago	66 (19.1)
≥2 years ago	26 (7.5)
Hypertension	110 (31.8)
Diabetes	16 (4.6)
High cholesterol	24 (6.9)
Stroke	18 (5.2)
Alcohol use⁺	
No	227 (65.6)
	, ,
Yes, drank in past, but quit	65 (18.8)
Yes, currently drink alcohol	54 (15.6)
Smoking status*	
Never	303 (87.6)
Ever	43 (12.4)
Medication use	

Table 3: Screening activities, access to medical services, and health conditions

Reported anti-hypertensive use	78 (22.5)
Reported aspirin use	89 (25.7)
Reported anti-cholesterol use	7 (2.0)
Reported herbal supplement use	233 (67.3)
Oral contraceptive use	
Never	175 (67.0)
Past use	64 (24.5)
Current use	22 (8.4)

Participants were asked "Have you had 10 or more drinks of alcohol in your life?"
 Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Т

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals, with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

Table 4: Insurance coverage and medical costs

Variable		n (%)
Insurance		
	No	331 (95.7)
	Yes	15 (4.3)
Last time used insurance		

In the last 2 years	6 (40.0)
>2 years ago	9 (60.0)
How many family members covered by insurance	
None	331 (95.7)
1-2	8 (2.3)
3-4	3 (0.9)
5 or more	4 (1.2)
Reasons for not having insurance (n=331)	
Expense	32 (9.7)
Lack of coverage	13 (3.9)
Too difficult to access	73 (22.1)
Other	217 (65.6)
Major medical costs in the last 2 years	
No	186 (53.8)
Yes	160 (46.2)
Estimated amount	
<10,000 Naira	73 (45.6)
10,000-49,000 Naira	38 (23.8)
50,000-99,999 Naira	16 (10.0)
>100,000 Naira	22 (13.8)
Unknown	11 (6.9)
Reasons for major medical costs (n=158)	17 (10.9)
Surgery Chronic conditions	17 (10.8)
Acute illness/trauma	52 (32.9) 74 (46.8)
Other/multiple reasons	15 (9.5)
Amount spent (continuous)	13 (9.3)
Amount spent (continuous)	10,000 (50-
Overall median (range)	1,500,000)
Median amount spent by reason (range)	
Surgery	60,000 (7,000- 150,000) 18,000 (500-
Chronic conditions	150,000)
Acute illness/trauma	5,000 (50-400,000)
Other/multiple reasons	70,000 (800- 500,000)

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education **Table 5**. Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels

BMJ Open

of education. No significant relationship was observed by insurance status or other factors that were assessed. In a multivariate logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

Table 5: Association between Cancer Screening Activity and Income, Insurance and Education N =310⁺

Variable	Cancer Screening (N=17)	No Cancer Screening (N=293)	P value*
Personal income (per month, in Naira)			
<10,000	2/138 (1.5)	140/138 (98.5)	
10,000-49,999	9/122 (7.4)	115/122 (92.6)	<0.01
>50,000	6/43 (14.0)	38/43 (86.0)	
Family income (per month, in			
Naira)	1/100 (0.0)	107/109 (00 1)	
<10,000	1/108 (0.9)	107/108 (99.1)	
10,000-49,999	8/129(6.2)	121/129(93.8)	<0.01
>50,000	8/66 (12.1)	58/66 (87.9)	
Insurance Status			
No	15/290 (5.2)	275/290 (94.8)	0.12
Yes	2/13 (15.4)	11/13 (84.6)	0.12
Education			
No formal education	1/86 (1.2)	85/86 (98.8)	
Primary	3/83 (3.6)	80/83 (96.4)	0.04
Secondary	8/78 (10.3)	70/78 (89.7)	0.04
Higher	5/56 (8.9)	51/56 (91.1)	

No association by Gender, Marital Status, Religion

* Adjusted for eligible population, whereby cancer screening activities defined as history of cervical assessment in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years

* Fisher's exact test for association

DISCUSSION

We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), ^{6 19 33} were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)³¹ and likely represent broad health and development deficiencies present in the community.

Previous studies conducted in the region ³⁴⁻⁴² have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.⁵ ⁴³ This highlights a need to develop sound health infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking and that the potential cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.³⁵ ³⁶ ⁴⁴⁻⁴⁷ The Nigerian "National Cancer Control Plan 2018-2022," specifically details goals to make screening services

BMJ Open

and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.²⁰. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022."²⁰ We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Our analysis provides some idea of how individuals have navigated health system and their degree of engagement different levels.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary alternative for early detection in low-resource settings.¹⁹ ⁴⁵ ⁴⁸ This has been recommended in local policy and was not assessed in the current study.²⁰ Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty

BMJ Open

as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.⁴⁹ Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.^{50 51} Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.^{14 15} Recent reports confirm that this expansion has been limited in Nigeria. In line with previous studies, our data indicate that the NHIS is severely underutilized in the community population.^{15 16} The state health insurance scheme has been instituted in

only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. ¹⁵

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.¹⁶ However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.⁵² Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region ⁵³ ⁵⁴, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.^{35 42 44 55} In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.⁵⁶ In addition, "demand-side" approaches to resource allocation, such as the stipend we provided for travel in the

BMJ Open

study or e-vouchers,^{57 58} are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated questionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition (e.g., resulted in more females than males). Nevertheless, overall consistency with national demographic indicators (e.g., income, education, and living conditions) indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.^{31 32}

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this, including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

to beet terien only

REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- 10. Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. *BMJ Case Reports* 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-215670
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- 12. Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. *Bull World Health Organ* 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

4

5

6 7

8

9

10

11

12 13

14

15

16

17 18

19

20

21

22

23 24

25

26

27

28 29

30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57

58

- 14. Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. Int J Health Policy Manag 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- 25. National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

 journal of public health 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. REPRODUCIBILITY AND VALIDITY OF A SEMIQUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. *Eur J Cancer Care (Engl)* 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 35. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. *Cancer Causes & Control* 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- 36. Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. *Journal of Global Oncology* 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 37. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
 [published Online First: 2016/12/30]
- 38. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]
- Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. Asian Pac J Cancer Prev 2010;11(1):137-40. [published Online First: 2010/07/03]
- 40. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 41. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]

- 42. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 43. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- 44. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- 45. Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- 46. Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 47. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- 49. Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 50. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 51. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. World J Surg 2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]
- 52. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 53. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 54. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and

1		
2		
3 4 5		
4		
5		
6 7		
/		
8		
9		
10		
11		
12		
13		
14 15		
15 16		
16 17		
18		
19		
20 21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49 50		
50		
51 52		
52		
53 54		
55 56		
56 57		
57 58		
20		

out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: https://doi.org/10.1016/S0140-6736(17)30874-7

- 55. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 56. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. JMIR Mhealth Uhealth 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 57. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 2018-000276 58. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

BMJ Open

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Journal:	BMJ Open	
Manuscript ID	bmjopen-2020-040352.R1	
Article Type:	Original research	
Date Submitted by the Author:	02-May-2021	
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics	
Primary Subject Heading :	Global health	
Secondary Subject Heading:	Oncology, Health services research, Public health	
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT	





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Sharma A. MD¹, Alatise O. I. MBChB², O'Connell K. MSc³, Gbenga O.S. MSc², Aderounmu A.A. MBChB², Samson. M.L. BSc³, Wuraola F. MBChB², Olasehinde O. MBChB, Kingham T.P MD¹, Du M. ScD³

¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; ²Obafemi Awolowo University, Ile-Ife, Nigeria; ³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

Acknowledgments: The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

Funding: This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's Center for Global Health to perform dedicated cancer research in the region. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Correspondence:

Avinash Sharma

2	
3	Memorial Sloan Kettering Cancer Center
4	
5	1275 Vork Avonue C 996
6	1275 York Avenue, C-886
7	New York, NY 10065
8	New York, NY 10065
9 10	
10	avinash.s.sharma@gmail.com
12	
13	
14	
15	Conflicts of Interest: None to declare
16	
17	
18	
19 20	
20 21	
22	
23	
24	
25	
26	
27	
28	
29	
30 31	
32	
33	
34	
35	
36	
37	
38	
39 40	
40	
42	
43	
44	
45	
46 47	
47 48	
40	
50	
51	
52	
53	
54	
55 56	
56 57	
58	
59	
60	

Author contributions:

1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

4. O.S. Gbenga

Author contributions: study organisation, data collection

5. A.A. Aderounmu

Author contributions: study organisation, data collection

6. M.L.Samson

Author contributions: study and questionnaire design

7. F. Wuraola

Author contributions: Manuscript revision

8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

10. **M. Du**

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

ABSTRACT

 Background/Aims: Cancer burden is predicted to double by 2030 in sub-Saharan Africa. Accordingly, access to healthcare services for cancer management has been made a priority in the region. In Nigeria, the National Cancer Control Plan aims to ensure greater than 50% cancer screening of eligible populations by 2022 for all Nigerians. This study sought to describe current healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria.

Methods: During April 2018, a cross-sectional study of community-based adults (>18 years) was conducted approximately 130 kilometers east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. A questionnaire was used to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

Results: A total of 346 individuals were enrolled; the median age was 52 years, and 75% of participants were female. Of the entire cohort, only 4% had medical insurance,. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent, with 1.5% of participants reporting having cervical cancer screening and 3.3% of participants >40 years having a mammogram. Colonoscopy screening in those >50 years was 5%. Cancer screening assessment was less frequent in those with less income and lower levels of education. Despite this, we observed that most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exist.

Conclusions: Despite expected increases in cancer cases, our data highlight a deficiency in cancer screening and lack of universal healthcare coverage within a

community-based adult Nigerian population. Increasing financial risk protection, awareness, and targeted resource allocation may help expand access.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

Strengths and Limitations of the study:

- The study provided a contemporary perspective potential barriers to accessing medical and cancer care in rural South-West Nigeria. Recruitment and data collection performed by interviewers fluent in the local dialect who underwent a systematic and rigorous two-day training program.
- Questionnaire tailored to the local population and developed in collaboration with local clinicians, epidemiologists, and nutritionists. Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
- 5) Survey conducted at a single time (mid-week, during the day) in two geographic locations, which may have affected sample composition (e.g., more females than males).

INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.¹⁻³ According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.^{4 5} In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.⁶⁻⁸ Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.⁹

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.^{7 10} In the region, out-of-pocket health expenditures are a major contributor to poverty ¹¹⁻¹³, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.¹⁴ However, uptake has been limited and restricted,¹⁵ and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.^{15 16}

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.¹⁷ The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.¹⁷⁻¹⁹ Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

BMJ Open

Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."²⁰ Despite this, the current state of cancer screening activities and barriers to care in this region (esp. rural areas) are not well-defined or documented. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. National programmes for screening breast and cervical cancer are lacking. Typically, screening interactions occur at primary health care facilities or community health clinics – often for women when they are being seen during pregnancy or for other related health issues such as immunisations. Screening services for cervical and breast cancer have been implemented sporadically by both government and non-government organisations but predominantly in urban areas. The overwhelming majority of individuals in the region are symptomatic when they present with disease. With 50 percent of Nigeria's population living in rural areas²¹ we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria²² investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.^{6 19 20 23} Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

METHODS

Study Design/Setting

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns ljebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the main tertiary referral center in the region. This study was part of a broader capacity building project in the region to improve cancer care. It was a baseline study to assess access to cancer services but also explore unique risk factors for cancer – such as diet, exercise, microbial and environmental exposures. The study was approved by the Obafemi Awolowo University institutional ethics review committee.

Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized all potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Participants were notified of the study through discussion at the weekly local community meetings in the month leading up to the study, advertisements on local radio-stations and through community workers visiting regional sites.

Participants

 Adults >18 years in the two towns were invited to participate. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Based on the resource capacity of each town hall and the size of each community, enrolment was to be capped at a maximum of 300 participants at ljebu-Jesa and 100 at Ere-Jesa. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

Questionnaire

The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication use, and environmental exposures. The questionnaire used was developed in collaboration with local clinicians, epidemiologists, and nutritionists, and was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,²⁴ Nigeria General Household Survey,²⁵ World Health Organization-endorsed Global Physical Activity Questionnaire,²⁶ and the Nurses' Health Study questionnaire.²⁷⁻³⁰

Data collection

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained

BMJ Open

research assistant. All research assistants underwent a two-day training program that involved education into the research aims, methodology, and ethics as well as interview techniques through role paying exercises, pilot testing of the questionnaire and the use of electronic tablets for recording data.

Outcome measures

Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. Demographic and socioeconomic data collected from our study population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator ^{31 32} to assess external validity.

Statistical analysis

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard

deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. Missing data were not possible for completed questionnaires as only complete responses to questions could be processed in order to advance the survey on the electronic tablets. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed. Enrolment was capped at this number to ensure complete surveys could be conducted for all individuals. All individuals that were interviewed provided data for analysis. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

Table 1: Demographic characteristics of the study group (n=346)

(n=268 ljebu-Jesa, n=68 Ere-Jesa)

Variable	n (%)
Median Age, years (range)	52 (18-100)
Sex	
Male	85 (24.6)
Female	261 (75.4)
Marital Status	
Single	27 (7.8)
Married	213 (61.6)
Other (Divorced/cohabiting)	106 (30.6)
Tribe	

Voruha	222 (06 0)
Yoruba	332 (96.0)
Ibo	5 (1.4)
Other	9 (2.6)
Religion	
Christian	326 (94.2)
Muslim	19 (5.5)
Other	1 (0.3)
Education	
No formal education	88 (25.4)
Primary	92 (26.6)
Secondary	92 (26.6)
Vocational/Technical	45 (13.0)
Higher	29 (8.4)
Occupation	
Unemployed	30 (8.7)
Civil servant	30 (8.7)
Trader	123 (35.5)
Farmer	35 (10.1)
Self-employed	80 (23.1)
Other	48 (13.9)
Number of Live Births (Females, n=242)	
0	6 (2.5)
1	15 (6.2)
2	23 (9.5)
3	28 (11.6)
4	54 (22.3)
5 or more	116 (47.9)

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian

Demographic and Health Survey (**Table 2b**).³¹ Both groups had similar degrees of education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,³² our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

Table 2a: Income and household conditions

Variable	n (%)
Personal income (per month, in Naira)	
<10,000	155 (44.8)
10,000-49,999	139 (40.2)
50,000-99,999	26 (7.5)
100,000-249,999	16 (4.6)
250,000-499,999	9 (2.6)
≥500,000	1 (0.3)
Family income (per month, in Naira)	
<10,000	117 (33.8)
10,000-49,999	147 (42.5)
50,000-99,999	38 (11.0)
100,000-249,999	28 (8.1)
250,000-499,999	11 (3.2)
≥500,000	5 (1.4)
Type of dwelling	
Own apartment	131 (37.9)
Rent apartment	146 (42.2)
Family house	67 (19.4)
Other	2 (0.6)
Type of toilet	
Water system	151 (43.6)
Pit latrine	164 (47.4)
Bush	23 (6.6)
Bucket	7 (2.0)
Other	1 (0.3)

Water source	
Pipe borne/boreholes	185 (53.5)
Well	146 (42.2)
River	15 (4.3)
Appliances	
Electricity	318 (91.9)
Television	262 (75.7)
Radio	251 (72.5)
Refrigerator	154 (44.5)
Air conditioner	8 (2.3)
Generating set	99 (28.6)
Personal computer	38 (11.0)
None	18 (5.2)

Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

	NDHS Urban	NDHS Rural	NDHS Total	Current study (%)
Cooking Fuel	(%)	(%)	(%)	
Cooking Fuel	0.7		0.4	40.7
Electricity	0.7	0.2	0.4	10.7
Liquefied petroleum gas/natural	4.6	0.5	2.3	21.1
Gas/biogas				
Kerosene	47.6	8.7	25.5	31.8
Charcoal	5.3	1.6	3.2	2.3
Wood	37.9	83.3	63.7	34.1
Electricity				
Yes	83.6	34.4	55.6	91.9
No	16.3	65.4	44.2	8.1
Missing	0.1	0.2	0.2	0
Household Appliances	•••			
Radio	77.7	61.3	68.3	72.5
Television	73.2	28.2	47.6	75.7
Refrigerator	32.5	7.5	18.3	44.5
Means of Transportation	02.0	1.0	10.0	11.0
Bicycle	12.7	18.3	18.3	0.9
Motorcycle/scooter	27.0	31.2	31.2	15.0
Car/truck	14.4	8.7	8.7	12.1
Education	14.4	0.7	0.7	12.1
Education			0	Our man the standay
	NDHS	NDHS	Current	Current study
	Female	Male	study	Male
	(%)	(%)	Female	(%)
			(%)	
No formal education	37.8	21.2	28.7	15.3
Primary	17.3	16.7	26.8	25.9
Secondary	35.8	47.7	28.0	22.4
	9.1	14.3	16.5	36.5

Within the group surveyed, cancer screening/assessment activities were limited: 2% (4/267) of female participants had a previous cervical smear/assessment, and 3% (6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was • t<u>o medical</u> also infrequent.

/ariable	n (%)	
Cancer screening		
Cervical Cancer assessment		
(if female > 21, n = 261)	4 (1.5)	
Previous mammogram (if		
female >40, n = 183)	6 (3.3)	
Previous colonoscopy (if >50 years, n = 190)	0 (4 5)	
ast primary health care physician	9 (4.5)	
visit		
<1 year ago	180 (52.0)	
1-4 years ago	93 (26.9)	
, ,	, , ,	
5-10 years ago	32 (9.2)	
>10 years ago	41 (11.8)	
ast time seen traditional healer		
Never	254 (73.4)	
<2 years ago	66 (19.1)	
≥2 years ago	26 (7.5)	
lypertension	110 (31.8)	
Diabetes	16 (4.6)	
ligh cholesterol	24 (6.9)	
Stroke	18 (5.2)	
Alcohol use ⁺		
No	227 (65.6)	
Yes, drank in past, but quit	65 (18.8)	
Yes, currently drink alcohol	54 (15.6)	

Table 3: Screening activities	access to medical services	, and health conditions

Smoking status*		
	Never	303 (87.6)
	Ever	43 (12.4)
Medication use		
Reported anti-hypertensive	use	78 (22.5)
Reported aspirin use		89 (25.7)
Reported anti-cholesterol u	Reported anti-cholesterol use	
Reported herbal supplement use		233 (67.3)
Oral contraceptive use		
	Never	175 (67.0)
	Past use	64 (24.5)
Cur	rent use	22 (8.4)

* Participants were asked "Have you had 10 or more drinks of alcohol in your life?"

* Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals, with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

Table 4: Insurance coverage and medical costs

Variable n (%)

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
20
22
23
24
25
26
27
27
28
29
30
31
32
33
34
35
36
37
37 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
55 54
55
56
57
58
50 59
59

1 2

Insurance		
	No	331 (95.7)
	Yes	15 (4.3)
Last time used insurance		
	In the last 2 years	6 (40.0)
	>2 years ago	9 (60.0)
How many family members co	overed by insurance	
	None	331 (95.7)
	1-2	8 (2.3)
	3-4	3 (0.9)
	5 or more	4 (1.2)
Reasons for not having insur	ance (n=331)	
	Expense	32 (9.7)
	Lack of coverage	13 (3.9)
	Too difficult to access	73 (22.1)
	Other	217 (65.6)
Major medical costs in the las	st 2 years	
	No	186 (53.8)
	Yes	160 (46.2)
Estimated amount		
	<10,000 Naira	73 (45.6)
	10,000-49,000 Naira	38 (23.8)
	50,000-99,999 Naira	16 (10.0)
	>100,000 Naira	22 (13.8)
	Unknown	11 (6.9)
Reasons for major medical co	osts (n=158)	0
	Surgery	17 (10.8)
	Chronic conditions	52 (32.9)
	Acute illness/trauma	74 (46.8)
	Other/multiple reasons	15 (9.5)
Amount spent (continuous)		
	o "" " ()	10,000 (50-
.	Overall median (range)	1,500,000)
Median amount spent by reas	on (range)	60,000 (7,000-
	Surgery	150,000
		18,000 (500-
	Chronic conditions	150,000)
	Acute illness/trauma	5,000 (50-400,000
	Other/multiple reasons	70,000 (800- 500,000)

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education **Table 5**.

Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels of education. No significant relationship was observed by insurance status or other factors that were assessed (gender, marital Status, religion). In a multivariate logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

Table 5: Association between Cancer	Screening Activity and Income, Insurance and
Education N =310 ⁺	

Variable	/ariable Cancer Screening (N=17)		P value*	
Personal income (per month, in				
Naira)				
<10,000	2/138 (1.5)	140/138 (98.5)		
10,000-49,999	9/122 (7.4)	115/122 (92.6)	<0.01	
>50,000	6/43 (14.0)	38/43 (86.0)		
Family income (per month, in				
Naira)				
<10,000	1/108 (0.9)	107/108 (99.1)		
10,000-49,999	8/129(6.2)	121/129(93.8)	<0.01	
>50,000	8/66 (12.1)	58/66 (87.9)		
Insurance Status				
No	15/290 (5.2)	275/290 (94.8)	0.10	
Yes	2/13 (15.4)	11/13 (84.6)	0.12	
Education				
No formal education	1/86 (1.2)	85/86 (98.8)		
Primary	3/83 (3.6)	80/83 (96.4)	0.04	
Secondary	8/78 (10.3)	70/78 (89.7)	0.04	
Higher	5/56 (8.9)	51/56 (91.1)		

No association by Gender, Marital Status, Religion

* Adjusted for eligible population, whereby cancer screening activities defined as history of cervical assessment in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years

* Fisher's exact test for association

DISCUSSION

 We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), ^{6 19 33} were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)³¹ and likely represent broad health and development deficiencies present in the community.

Previous studies conducted in the region ³⁴⁻⁴² have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.^{5 43} This highlights a need to develop sound healthcare infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking through either delivery and/or uptake, and that the potential cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.^{35 36 44-47} The Nigerian "National Cancer Control Plan 2018-2022,"

Page 23 of 34

BMJ Open

specifically details goals to make screening services and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.²⁰. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022."²⁰ We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Whilst our analysis provides some idea of how individuals may have navigated the health system further detailed study is required to look at specific engagement at these different levels to inform appropriate resource allocation.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary alternative for early detection in low-resource settings.^{19 45 48} This has been recommended in local policy and was not assessed in the current study.²⁰ Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer

BMJ Open

screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.⁴⁹ Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.^{50 51} Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.^{14 15} Recent reports confirm that this expansion has been limited in Nigeria. In line with

BMJ Open

previous studies, our data indicate that the NHIS is severely underutilized in the community population.^{15 16} The state health insurance scheme has been instituted in only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. ¹⁵

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.¹⁶ However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.⁵² Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region ^{53 54}, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.^{35 42 44 55} In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.⁵⁶ In addition, "demand-side"

 approaches to resource allocation, such as the stipend we provided for travel in the study or e-vouchers,^{57 58} are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated guestionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. Whilst we have documented low levels of screening activities and associations with income and education, we did not directly require individuals to state specifically their personal reasons for not being screened to delineate availability, awareness or finances. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition (e.g., resulted in more females than males). Nevertheless, overall consistency with national demographic indicators (e.g., income, education, and living conditions) indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.^{31 32}

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this,

 including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

to beet terier only

Ethical Approval Statement

The study was approved by the Obafemi Awolowo University institutional ethics review committee. Further details available directly from: Obafemi Awolowo University Teaching Hospitals Complex, ILE-IFE, NIGERIA. Ethics and Research Committee

Mr. M.O. Adeyeye,

Head.Clinical Services and Training,

OAUTHC, lle-lfe. 08032430923

Or

Ms. B. A. Ayoola 08068810690

Desk Officer, Ethics and Research Committee

terez onz

REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. BMJ Case Reports 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- 12. Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. *Bull World Health Organ* 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

4

5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28 29

30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57

58

- 14. Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. Int J Health Policy Manag 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- 25. National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

journal of public health 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. REPRODUCIBILITY AND VALIDITY OF A SEMIQUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- 34. Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. Eur J Cancer Care (Engl) 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 35. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. *Cancer Causes & Control* 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- 36. Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. *Journal of Global Oncology* 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 37. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
 [published Online First: 2016/12/30]
- 38. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]
- Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. Asian Pac J Cancer Prev 2010;11(1):137-40. [published Online First: 2010/07/03]
- 40. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 41. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]

- 42. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 43. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- 44. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- 45. Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- 46. Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 47. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- 49. Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 50. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 51. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. World J Surg 2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]
- 52. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 53. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 54. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and

2	
3	
4	
5	
6	
7	
, 8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32 33	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
44 45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
55 56	
57	
58	

59 60 out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: <u>https://doi.org/10.1016/S0140-6736(17)30874-7</u>

- 55. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 56. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. *JMIR Mhealth Uhealth* 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 57. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 2018-000276
 58. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

1	
2	
3	
4	
5	
6	
-	
7	
8	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
~ ~	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
47 48	
49	
50	
51	
52	
53	
54	
54 55	
56	
57	
58	
59	
60	

STROBE Statement—Checklist of items that should b	be included in reports of <i>cross-sectional studies</i>
	-

	Item No	Recommendation	Page No
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title	4
		or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	4
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	8,9
C		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	9
Methods			
Study design	4	Present key elements of study design early in the paper	10,11
Setting	5	Describe the setting, locations, and relevant dates, including periods of	10
0		recruitment, exposure, follow-up, and data collection	-
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	10
1		selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	10
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	11
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10,11
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	11
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	12,13
		(b) Describe any methods used to examine subgroups and interactions	12,13
		(c) Explain how missing data were addressed	13
		(<i>d</i>) If applicable, describe analytical methods taking account of	n/a
		sampling strategy	
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	13
Ĩ		potentially eligible, examined for eligibility, confirmed eligible,	
		included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	13,14
-		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable	n/a
Outrouve let	1.7.4	of interest	14171
Outcome data	15*	Report numbers of outcome events or summary measures	14,15,1

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	15,16
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	n/a
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	n/a
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and	n/a
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	21
Limitations	19	Discuss limitations of the study, taking into account sources of	21-25
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	21-25
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	21-25
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	1
		study and, if applicable, for the original study on which the present	
		article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

BMJ Open

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040352.R2
Article Type:	Original research
Date Submitted by the Author:	28-Jun-2021
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics
Primary Subject Heading :	Global health
Secondary Subject Heading:	Oncology, Health services research, Public health
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Sharma A. MD¹, Alatise O. I. MBChB², O'Connell K. MSc³, Ogunleye S.G. MSc², Aderounmu A.A. MBChB², Samson. M.L. BSc³, Wuraola F. MBChB², Olasehinde O. MBChB, Kingham T.P MD¹, Du M. ScD³

¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; ²Obafemi Awolowo University, Ile-Ife, Nigeria; ³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

Acknowledgments: The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

Correspondence:

Avinash Sharma

Memorial Sloan Kettering Cancer Center

1275 York Avenue, C-886

New York, NY 10065

avinash.s.sharma@gmail.com

ABSTRACT

Background/Aims: Cancer burden is predicted to double by 2030 in sub-Saharan Africa; access to healthcare services for cancer management is a priority in the region. In Nigeria, National Cancer Control Plan aims to ensure >50% cancer screening of eligible populations by 2022 for all Nigerians. We describe healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within an understudied rural community-based adult population in South-West Nigeria.

Methods: In April 2018, we conducted a cross-sectional study of community-based adults (>18 years) ~130 kilometres east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. We used a questionnaire to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

Results: We enrolled 346 individuals; with median age of 52 years, and 75% female. Of the entire cohort, 4% had medical insurance. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent in eligible participants: 1.5% reported having had cervical cancer screening, 3.3% mammogram, and 5% colonoscopy screening. Cancer screening assessment was less frequent in those with less income and lower education levels. Using a multivariable logistic regression model including personal income, insurance status, and education, higher personal income was associated with more cancer screening activity (OR 2.7 95%CI 1.3-5.7 p<0.01). Despite this, most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exists.

Conclusions: Despite national increases in cancer cases, we highlight a deficiency in cancer screening and universal healthcare coverage within a community-based adult Nigerian population. Subject to availability of governmental resources, increasing financial risk protection, awareness, and targeted resource allocation may help expand access in Nigeria.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

Strengths and Limitations of the study:

- 1) Rigorously trained interviewers fluent in the local dialect collected contemporary perspectives of potential barriers to accessing medical and cancer care in a crucially understudied population in rural South-West Nigeria.
- Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys and tailored to the local population in collaboration with local clinicians, epidemiologists, and nutritionists.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
- 5) Survey conducted at a single time (mid-week, during the day) in two geographic locations, which may have affected sample composition (e.g., more females than males).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.¹⁻³ According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.^{4 5} In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.⁶⁻⁸ Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.⁹

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.^{7 10} In the region, out-of-pocket health expenditures are a major contributor to poverty ¹¹⁻¹³, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.¹⁴ However, uptake has been limited and restricted,¹⁵ and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.^{15 16}

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.¹⁷ The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.¹⁷⁻¹⁹ Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

BMJ Open

Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."²⁰ Despite this, the current state of cancer screening activities and barriers to care in this region (esp. rural areas) are not well-defined or documented. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. National programmes for screening breast and cervical cancer are lacking. Typically, screening interactions occur at primary health care facilities or community health clinics – often for women when they are being seen during pregnancy or for other related health issues such as immunisations. Screening services for cervical and breast cancer have been implemented sporadically by both government and non-government organisations but predominantly in urban areas. The overwhelming majority of individuals in the region are symptomatic when they present with disease. With 50 percent of Nigeria's population living in rural areas²¹ we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria²² investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.⁶ ¹⁹ ²⁰ ²³ Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

METHODS

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns ljebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the main tertiary referral center in the region. This study was part of a broader capacity building project in the region to improve cancer care and prevention in this understudied population. It served as a baseline study to assess access to cancer services as well as a pilot study to explore endemic risk factors for cancer – such as unique dietary, exercise and environmental exposures.

Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized all potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Participants were notified of the study through discussion at the weekly local community meetings in the month leading up to the study, advertisements on local radio-stations and through community workers visiting regional sites.

Participants

BMJ Open

Adults >18 years in the two towns were invited to participate. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Sample size for this study was therefore based on resource capacity of each town hall, available number of interviewers to administer the questionnaire, and the size of each rural community in which we recruited; enrolment was capped at a maximum of 300 participants at Ijebu-Jesa and 100 at Ere-Jesa over the recruitment period. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

Questionnaire

The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication use, and environmental exposures. (See supplementary file). The questionnaire used was developed in collaboration with local clinicians, epidemiologists, and nutritionists, and was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,²⁴ Nigeria General Household Survey,²⁵ World Health Organization-endorsed Global Physical Activity Questionnaire,²⁶ and the Nurses' Health Study questionnaire.²⁷⁻³⁰ We therefore did not additionally test for reliability and our study was intended to capture a cross-sectional snapshot of our rural communities. However, we expect low social mobility in our two rural Nigerian towns

and therefore limited changes over time for the sociodemographic features collected in our questionnaire.

Data collection

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained research assistant. All research assistants underwent a two-day training program that involved education into the research aims, methodology, and ethics as well as interview techniques through role paying exercises, pilot testing of the questionnaire and the use of electronic tablets for recording data.

Outcome measures

Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. Demographic and socioeconomic data collected from our study

BMJ Open

population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator ^{31 32} to assess external validity.

Statistical analysis

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. Missing data were not possible for completed questionnaires as only complete responses to questions could be processed in order to advance the survey on the electronic tablets. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

(elie

RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed during the recruitment period. All individuals that were interviewed provided data for analysis. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

Table 1: Demographic characteristics of the study group (n=346)

(n=268 ljebu-Jesa, n=68 Ere-Jesa)

1
2
3
4
5
6 7
8
9
10
11
12 13
13
14
15
16
17
13 14 15 16 17 18 19
10
20
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
22
23
24
25
26
27
27
20
29
30
31
32
33
34 35
35
36
37
38
39
40
41
42
43
44
44 45
45 46
46 47
48
49
50
51
52
53
54
55
56
57
58
58 59

1

Variable	n (%)
Median Age, years (range)	52 (18-100)
Sex	
Male	85 (24.6)
Female	261 (75.4)
Marital Status	
Single	27 (7.8)
Married	213 (61.6)
Other (Divorced/cohabiting)	106 (30.6)
Tribe	
Yoruba	332 (96.0)
Ibo	5 (1.4)
Other	9 (2.6)
Religion	
Christian	326 (94.2)
Muslim	19 (5.5)
Other	1 (0.3)
Education	
No formal education	88 (25.4)
Primary	92 (26.6)
Secondary	92 (26.6)
Vocational/Technical	45 (13.0)
Higher	29 (8.4)
Occupation	
Unemployed	30 (8.7)
Civil servant	30 (8.7)
Trader	123 (35.5)
Farmer	35 (10.1)
Self-employed	80 (23.1)
Other	48 (13.9)
Number of Live Births (Females, n=242)	
0	6 (2.5)
1	15 (6.2)
2	23 (9.5)
3	28 (11.6)
4	54 (22.3)
5 or more	116 (47.9)

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a

 family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian Demographic and Health Survey (**Table 2b**).³¹ Both groups had similar degrees of education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,³² our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

Table 2a: Income and household conditions

Variable	n (%)
Personal income (per month, in Naira)	
<10,000	155 (44.8)
10,000-49,999	139 (40.2)
50,000-99,999	26 (7.5)
100,000-249,999	16 (4.6)
250,000-499,999	9 (2.6)
≥500,000	1 (0.3)
Family income (per month, in Naira)	
<10,000	117 (33.8)
10,000-49,999	147 (42.5)
50,000-99,999	38 (11.0)
100,000-249,999	28 (8.1)
250,000-499,999	11 (3.2)
≥500,000	5 (1.4)

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
57	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1 2

Type of dwelling	
Own apartment	131 (37.9)
Rent apartment	146 (42.2)
Family house	67 (19.4)
Other	2 (0.6)
Type of toilet	
Water system	151 (43.6
Pit latrine	164 (47.4
Bush	23 (6.6)
Bucket	7 (2.0)
Other	1 (0.3)
Water source	
Pipe borne/boreholes	185 (53.5
Well	146 (42.2
River	15 (4.3)
Appliances	
Electricity	318 (91.9
Television	262 (75.7
Radio	251 (72.5
Refrigerator	154 (44.5
Air conditioner	8 (2.3)
Generating set	99 (28.6)
Personal computer	38 (11.0)
None	18 (5.2)

Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

	NDHS Urban (%)	NDHS Rural (%)	NDHS Total (%)	Current study (%)
Cooking Fuel				
Electricity	0.7	0.2	0.4	10.7
Liquefied petroleum gas/natural Gas/biogas	4.6	0.5	2.3	21.1
Kerosene	47.6	8.7	25.5	31.8
Charcoal	5.3	1.6	3.2	2.3
Wood	37.9	83.3	63.7	34.1
Electricity				
Yes	83.6	34.4	55.6	91.9
No	16.3	65.4	44.2	8.1
Missing	0.1	0.2	0.2	0
Household Appliances				
Radio	77.7	61.3	68.3	72.5
Television	73.2	28.2	47.6	75.7
Refrigerator	32.5	7.5	18.3	44.5
Means of Transportation				
Bicycle	12.7	18.3	18.3	0.9
Motorcycle/scooter	27.0	31.2	31.2	15.0
Car/truck	14.4	8.7	8.7	12.1

Education				
	NDHS Female (%)	NDHS Male (%)	Current study Female	Current study Male (%)
			(%)	
No formal education	37.8	21.2	28.7	15.3
Primary	17.3	16.7	26.8	25.9
Secondary	35.8	47.7	28.0	22.4
More than secondary	9.1	14.3	16.5	36.5

Within the group surveyed, cancer screening/assessment activities were limited: 2% (4/267) of female participants had a previous cervical smear/assessment, and 3% (6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was also infrequent.

Variable	n (%)	
Cancer screening		
Cervical Cancer assessment		
(if female > 21, n = 261)	4 (1.5)	
Previous mammogram (if		
female >40, n = 183)	6 (3.3)	
Previous colonoscopy (if >50		
years, n = 190)	9 (4.5)	
Last primary health care physician		
visit		
<1 year ago	180 (52.0)	
1-4 years ago	93 (26.9)	
5-10 years ago	32 (9.2)	
>10 years ago	41 (11.8)	
Last time seen traditional healer		

Table 3: Screening activities, access to medical services, and health conditions

Never	254 (73.4)
<2 years ago	66 (19.1)
≥2 years ago	26 (7.5)
Hypertension	110 (31.8)
Diabetes	16 (4.6)
High cholesterol	24 (6.9)
Stroke	18 (5.2)
Alcohol use⁺	
No	227 (65.6)
Yes, drank in past, but quit	65 (18.8)
Yes, currently drink alcohol	54 (15.6)
Smoking status*	
Never	303 (87.6)
Ever	43 (12.4)
Medication use	
Reported anti-hypertensive use	78 (22.5)
Reported aspirin use	89 (25.7)
Reported anti-cholesterol use	7 (2.0)
Reported herbal supplement use	233 (67.3)
Oral contraceptive use	
Never	175 (67.0)
Past use	64 (24.5)
Current use	22 (8.4)
	_

* Participants were asked "Have you had 10 or more drinks of alcohol in your life?"

* Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals,

BMJ Open

with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

Table 4: Insurance coverage and medical costs

Variable		n (%)
Insurance		
	No	331 (95.7)
	Yes	15 (4.3)
Last time used insurance		
In the la	ast 2 years	6 (40.0)
>2	years ago	9 (60.0)
How many family members covered by ins	surance	
	None	331 (95.7)
	1-2	8 (2.3)
	3-4	3 (0.9)
	5 or more	4 (1.2)
Reasons for not having insurance (n=331)		
	Expense	32 (9.7)
Lack o	f coverage	13 (3.9)
Too difficult	t to access	• 73 (22.1)
	Other	217 (65.6)
Major medical costs in the last 2 years		
	No	186 (53.8)
	Yes	160 (46.2)
Estimated amount		
<10	,000 Naira	73 (45.6)
10,000-49	,000 Naira	38 (23.8)
50,000-99	,999 Naira	16 (10.0)
>100	,000 Naira	22 (13.8)
	Unknown	11 (6.9)
Reasons for major medical costs (n=158)		
	Surgery	17 (10.8)
Chronic	conditions	52 (32.9)
Acute illne	ess/trauma	74 (46.8)
Other/multip	le reasons	15 (9.5)
Amount spent (continuous)		
Overall medi	an (range)	10,000 (50- 1,500,000)
Median amount spent by reason (range)	an (range)	1,000,000)
median amount spent by reason (range)		60,000 (7,000-
	Surgery	150,000)
Chronic	oonditions	18,000 (500-
Chronic	conditions	150,000)

Acute illness/trauma Other/multiple reasons 5,000 (50-400,000) 70,000 (800-500,000)

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education **Table 5**. Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels of education. No significant relationship was observed by insurance status or other factors that were assessed. In a multivariable logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

Variable	Cancer Screening	No Cancer Screening (N=293)	P value*
Personal income (per month, in			
Naira)			
<10,000	2/138 (1.5)	140/138 (98.5)	
10,000-49,999	9/122 (7.4)	115/122 (92.6)	<0.01
>50,000	6/43 (14.0)	38/43 (86.0)	
Family income (per month, in			
Naira)			
<10,000	1/108 (0.9)	107/108 (99.1)	
10,000-49,999	8/129(6.2)	121/129(93.8)	<0.01
>50,000	8/66 (12.1)	58/66 (87.9)	
Insurance Status			
No	15/290 (5.2)	275/290 (94.8)	0.40
Yes	2/13 (15.4)	11/13 (84.6)	0.12
Education			
No formal education	1/86 (1.2)	85/86 (98.8)	
Primary	3/83 (3.6)	80/83 (96.4)	0.04
Secondary	8/78 (10.3)	70/78 (89.7)	

Table 5: Association between Cancer Scr	eening Activity and Income,	Insurance and
Education N =310 ⁺		

1 2				
- 3 4	Higher	5/56 (8.9)	51/56 (91.1)	
5				
6 7	No association by Gender, Marital Status, Religion	ı		
8 9	* Adjusted for eligible population, whereby cancer mammogram in women >40 years, and colonosco		ory of cervical assessment in women	n >21 years,
10 11	* Fisher's exact test for association	, , ,		
12				
13 14				
15 16				
17 18				
19				
20 21				
22 23				
24 25				
26				
27 28				
29 30				
31 32				
33 34				
35				
36 37				
38 39				
40 41				
42				
43 44				
45 46				
47 48				
49				
50 51				
52 53				
54 55				
56				
57 58				
59 60				

DISCUSSION

We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), ^{6 19 33} were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)³¹ and likely represent broad health and development deficiencies present in the community. For example, the high prevalence of hypertension in this population is remarkably similar to that reported in a systematic review and meta-analysis conducted in the region.³⁴ ³⁵ The high burden of hypertension in the region has also been recently acknowledged by the World Health Organization in its efforts to control hypertension in Nigeria.³⁶

Previous studies conducted in the region ³⁷⁻⁴⁵ have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.^{5 46} This highlights a need to develop sound healthcare infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking through either delivery and/or uptake, and that the potential

Page 21 of 45

BMJ Open

cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.^{38 39 47-50} The Nigerian "National Cancer Control Plan 2018-2022," specifically details goals to make screening services and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.²⁰. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022.²⁰ We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Whilst our analysis provides some idea of how individuals may have navigated the health system further detailed study is required to look at specific engagement at these different levels to inform appropriate resource allocation.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary

BMJ Open

alternative for early detection in low-resource settings.^{19 48 51} This has been recommended in local policy and was not assessed in the current study.²⁰ Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.⁵² Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.^{53 54} Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state

Page 23 of 45

BMJ Open

governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.^{14 15} Recent reports confirm that this expansion has been limited in Nigeria. In line with previous studies, our data indicate that the NHIS is severely underutilized in the community population.^{15 16} The state health insurance scheme has been instituted in only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. ¹⁵

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.¹⁶ However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.⁵⁵ Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region ^{56 57}, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.^{38 45 47 58} In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting **BMJ** Open

that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.⁵⁹ In addition, "demand-side" approaches to resource allocation, such as the stipend we provided for travel in the study or e-vouchers,^{60 61} are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated questionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. Whilst we have documented low levels of screening activities and associations with income and education, we did not directly require individuals to state specifically their personal reasons for not being screened; we were therefore unable to delineate specific barriers to cancer screening, such as emotional barriers (e.g., concern about cancer diagnosis, limited awareness) and barriers to access (e.g., screening locations, availability of transportation, limited finances, etc.). Detailed qualitative analysis of these barriers would be worthwhile and is the subject of our future work in the region. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was

BMJ Open

conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition. For instance, 75% of participants in our study were female, which may potentially limit the generalizability of our findings. However, it is reassuring we observed overall consistency with national demographic indicators (e.g., income, education, and living conditions), which indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.^{31 32}

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this, including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

terez onz

BMJ Open

Ethical Approval Statement

The study was approved by the Obafemi Awolowo University institutional ethics review committee.

Author contributions:

1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

4. S.G Ogunleye

Author contributions: study organisation, data collection, manuscript revision

5. A.A. Aderounmu

Author contributions: study organisation, data collection, manuscript revision

6. M.L.Samson

Author contributions: study and questionnaire design, manuscript revision

7. F. Wuraola

Author contributions: study design, questionnaire design, manuscript revision

8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

10. **M. Du**

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

Competing Interests: None to declare

Funding: This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's (NCI) Center for Global Health to perform dedicated cancer research in the region. This research was supported by the National Cancer Institute grant numbers R01 CA246620 and P30 CA008748.

Data sharing: No additional data available

REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- 10. Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. *BMJ Case Reports* 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-215670
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bull World Health Organ 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

2	
3 4	
4	
5	
6 7 8 9	
/	
8	
9 10	
10 11	
11 12	
12 13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
20 21 22 23 24 25 26 27 28	
28	
29	
30	
31	
32	
33 34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
50 51	
51	
52 53	
55 54	
55	
56	
57	
58	
59	
60	

- 14. Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. *Int J Health Policy Manag* 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- 22. Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- 25. National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

4

5

6 7

8

9

10

11

12 13

14

15

16

17 18

19

20

21

22

23 24

25

26

27

28 29

30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57

58

59

60

journal of public health 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and Validity of a Semiquantitative Food Frequency Questionnaire. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- 34. Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. *J Hypertens* 2015;33(2):230-42. doi: 10.1097/hjh.000000000000413 [published Online First: 2014/11/08]
- 35. Idris IO, Oguntade AS, Mensah EA, et al. Prevalence of non-communicable diseases and its risk factors among Ijegun-Isheri Osun residents in Lagos State, Nigeria: a community based cross-sectional study. *BMC Public Health* 2020;20(1):1258. doi: 10.1186/s12889-020-09349-2
- 36. Nigeria collaborates with WHO to curb hypertension, introduces control initiative Abeokuta, Nigeria: World Health Organisation; December 2020 [Available from: <u>https://www.afro.who.int/news/nigeria-collaborates-who-curb-hypertension-</u> <u>introduces-control-</u> <u>initiative#:~:text=The%20review%20estimated%20that%20prevalence 29 5%25%2C</u>

initiative#:~:text=The%20review%20estimated%20that%20prevalence,29.5%25%2C %20women%2031.1%25). accessed 15 April 2021 2021.

- Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. *Eur J Cancer Care (Engl)* 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 38. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. Cancer Causes & Control 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. *Journal of Global Oncology* 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 40. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
 [published Online First: 2016/12/30]
- 41. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level

2	
3	
4	
5	
6	
-	
/	
8	
9	
1	0
1	1
1	2
1	3
14	
1	
10	б
1	7
1	, n
- 10	ð
1	9
2	0
2	
2	n
	2
2	
24	4
2	5
2	b
2	7
2	8
2	
3	
3	1
3	2
3	
34	
3	5
3	6
2	7
3	/
3	8
3	9
4	0
4	
4	2
4	3
4	4
4	-
4	
4	7
4	
4	
5	
5	1
5	2
5	2 3
54	
5	5
5	
5	
5	
5	9
6	

medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]

- 42. Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. *Asian Pac J Cancer Prev* 2010;11(1):137-40. [published Online First: 2010/07/03]
- 43. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 44. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]
- 45. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 46. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- 47. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- 48. Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 50. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- 51. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 53. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 54. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. *World J Surg*

BMJ Open

2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]

- 55. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 56. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 57. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: <u>https://doi.org/10.1016/S0140-6736(17)30874-7</u>
- 58. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 59. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. *JMIR Mhealth Uhealth* 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 60. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 61. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

3 of 45				DIVI.	J Open			Page	1 of 12	
Participant II	D:		COLOREC	TAL CASE	E / BREA	AST CASE	. / CONTR	OL (CIRCLI	E ONE)	
-	site:					MA	LE / FEMA	LE (CIRCLI	E ONE)	
Interviewer I	D:			Date q	uestionna	ire adm	inistered:			
Phone Numb	er	⊦	lospital Nu	umber						
Patient Surna	ame:				Patier	nt First N	ame:			
PLEASE NOTE PLEASE ENTE	TION IS STRICT IN COVER SHE R ALL WRITTEN R ALL NUMBER	ET REASON	FOR NON- G ONLY CA	RESPONS PITAL LET	E TO ANY TERS.	QUESTI	ONS.	SES ONLY.		
Demographi	c History									
1. What is you	r date of birth (D	AY/MONTH/	(EAR)?	/	/					
2. (FOR CASES	ONLY) When did	you last feel	well (i.e., m	nostly una	ffected by	pain/dise	comfort)?	(month	s ago)	
3. (FOR CASES	ADD: When you	were well) wl	hat is/was y	our weigł	nt? (<i>Meası</i>	ure to neo	arest kg)		(kg)	
4. Has your we	eight changed (+,	′- 5 kg) in the	past 2 year	s? 🗌 No	<u> </u>	ncreased	5 kg	Decrea	sed 5 kg	
5. Which diag	am best depicts	your <u>outline</u> a	at each age	?						
RR	R. R.	QQ.	Q D	LA				Indicate (1 to 9)	diagram	
AND	ANA A	IL IL	E.) /E.	3 / 3	{	Age	10 years	(1 (0 5)		
	of the of the	TO AT	F F	9 H	ŧ		20 years			
16 18		JL JL	JI JI	1 11			, 30 years (<i>if</i>			
1 2	3 4	56	7 8	9			icable)			
Ł Ł	& & &		RA	A			40 years (if icable)			
AS AS	E E E	TETE	A.				50 years (<i>if</i>			
W.W.		1111		T P		Curr	icable)			
28 28	20 20 2		1 20	20		Curr				
6. What is you	r height? (<i>Meası</i>	ire to nearest	ст)	(cm)					
7. What is you	r current marital	status? 🗌 Si	ingle] Widowe	d 🗌 N	Married	Divor	ced		
	in your immedia	, , ,		•	nildren) co	mpleted	secondary sch	nool or abo	ve? 🗌 Yes	
9. What is the	highest education	nal level you	have comp	leted?						
🗌 No formal	education 🗌 Pi	imary 🗌 Seo	condary 🗌	Vocatior	nal/technic	al 🗌 Ur	niversity 🗌 (Graduate so	chool	
10. What is/w	as your occupati	on at the follo	wing 2 time	e periods ?)					
	Unemployed	Pensioner	Civil Servant	Trader	Farmer	Driver	Self Employed	Retired	Student	Other
Current							Linpioyeu			
Less than 2										
years ago										
More than										
2 years ago										
11. What is yo	ur current religio	on? 🗌 Christi	an 🗌	Muslim	□ 1	radition	al 🗌 Othe	r	_(specify)	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Page 2 of 12

		LGA/Distri	ct	Landmark	Villa	ge Name
1	3. What tribe do you belor	ng to? 🗌 Yoruba	🗌 Ibo	🗌 Hausa	Other	(specify)
14	4. Including yourself, how	many people live i	n your househol	d?		
1	5. Including you, what was	your <u>household's</u>	AVERAGE MON	THLY combined income	(including all sour	ces) over the last year?
_		Refused/Don't I				
		If refused/don't vour household's /		HLY combined income la	ast vear less than 2	21000 Naira? 🗌 Yes 🗌 No
				HLY combined income la		
1	6. What was your <u>persona</u>	AVERAGE MONTH	ILY income (incl	uding all sources) over t	he last year?	
_		Refused/Don't I				
	16a. Was		RAGE MONTHLY	' income last year less th ' income last year less th		Yes No
1]	7. What type of toilet do y			m (flushable) 🗌 Pit lat	rine with vent pip	e 🗌 Unventilated pit latrine
1	8. Is your toilet shared wit	h another househo	ld? 🗌 Yes	No		
1 9	9. What is the source of yo River/spring	our water supply? [Rain harvested		Public tap Bo Other	orehole or pump	Dug well
_	0. Is your source of water] Yes □ No ↓ If no	ocated within you	r compound?			
	20a. Is your water	source more than	30 minutes away	y by foot (to and from)?	Yes No)
2	 Does the construction o 	f your source of w	ater protect the	water from outside con	tamination? 🗌 Ye	es 🗌 No 📄 Don't Know
2 2	 What type of floor do yo Cement Tile [me?] Dirt/clay/eartl	n 🗌 Sand	Dung	Other
2 :	3. Which of these do you h Electricity (Connected to Air conditioner		ower grid)	Television Ra	=	frigerator 🔲 Telephone ble (DSTV, etc.)
	4. What is your <u>primary</u> co Charcoal or coal			Electric cooker Other	Gas cooker	Kerosene stove
_	5. Do you own any of the f Personal car or truck		s many as may a] Motorcycle		mobiles	
	6. Do you have National H ☐Yes ☐No (go to quest ∠If yes	•	HIS)?			
2	6a. When did you last use 6b. Including yourself, hov					
_	7. If no insurance, what ar] Too Expensive [] Unaware of the NHIS [Doesn't cover m	-	ance? (Select as many a s/costs		
	8. Did you have any major]Yes □No ⁄If yes	medical costs in th	ne last 2 years (ro	egardless of insurance st	tatus)?	
	8a. Please specify what for			and estimated cost	(Na	aira)
		For peer review o	nly - http://bmjc	pen.bmj.com/site/abou	ut/guidelines.xhtr	nl

						(If <u>newly</u> dia	ar of diagnos agnosed mult ct all that app	is iple times,	I	bei	ntly ng ed?
	Y	es	N	lo	If Yes →	More than 10 years ago	5 to 10 years ago	Less than 5 years ago	Yes	- T	No
Tuberculosis (TB)	Γ		Γ				1	1]	
Malaria										j	
HIV]	
Hepatitis B (HBV)]	
Hepatitis C (HCV)]	
Amoebic infection]	
Schistosomiasis]	
Giardia]	
Other parasitic infection (specify)			Ē	-]	
Chronic Obstructive]	
Pulmonary Disease (COPD)	<u> </u>	_	_								
Sickle Cell Disease (SCD)	ļĹ	<u> </u>						1		ļļ	
Peptic Ulcer Disease											
Diabetes											
Hypertension (high blood pressure)		_		_]	
Myocardial infarction (heart attack)]	
High cholesterol]	
Stroke or mini-stroke		<u> </u>									
Asthma		_									
Epilepsy		_									
Cancer (specify)							\mathbf{C}			J	
 30. (FOR CASES ADD: Prior to Less than 1 year ago Less than 1 year ago Yes No (go t Ves No (go t Ves No (go t Ves Saw <2 YEARS AGO Saw 2+ YEARS AGO 3aw 2+ YEARS AGO 3au 2+ YEARS AGO 3au 2+ YEARS AGO] 1-4 dition to qu	yea nal l iest	ars a hea	ago Ier?	5-10		More than		ived (udr	e in a
32. Do you use traditional rer	medi	es a	at h	ome	e?						
☐ Yes(↓ If yes ☐ Used <2 YEARS AGO ☐ Used 2+ YEARS AGO	spec	ify)			🗌 No (go t	to question 33)					

Stool test 22 YEARS AGO Stool test 24 YEARS AGO 33a. Did you receive any treatment? Yes (specify) No 34. (FOR WOMEN ONLY) Have you ever had cervical cancer screening? (e.g. Pap smear, HPV testing) *collecting cells from cervix to test for cancer* (e.g. Pap smear, HPV testing) *collecting cells from cervix to test for cancer* (e.g. Mammogram) *collecting cells from cervix to test for cancer screening? (e.g. Mammogram) *x-ray of breasts* (a.g. Mammogram <2 YEARS AGO) (breasts* (a.g. Mammogram <2 YEARS AGO) (breasts* (breasts* (c.g. Mammogram <2 YEARS AGO) (breasts* (breasts* (c.g. Mammogram 24 YEARS AGO) (breasts*	Screening History									
intestines/colon via inserted camera* □ Colonoscopy/Sigmoldoscopy 10+ YEARS AGO □ Stool test < 2 YEARS AGO □ Stool test < 2 YEARS AGO □ Yes	e.g., Colonoscopy/sigmoidoscopy, sto	ol test)	↓ If y	es (Select	all that ap	oply.)			rd of this (g	o to questi
34. (FOR WOMEN ONLY) Have you ever had cervical cancer screening? (e.g. Pap smear, HPV testing) *collecting cells from cervix to test for cancer* 35. (FOR WOMEN ONLY) Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* Sa. (FOR WOMEN ONLY) Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* (e.g. Mammogram <2 YEARS AGO			Co St	olonoscopy ool test <2	/sigmoid YEARS A	oscopy 10+ \ GO				
Have you ever had cervical cancer screening? Yes No (go to question 35) Never heard of this (go to question 35) Never heard of this (go to question 35) Yes Cervical cancer screening 3 YEARS AGO Ster 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) 36. Have any of these relatives had the following cancers? (Select as many as may apply.) Second the following cancers? (Select as many as may apply.) Teamily History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) Teamily history of cancer (go to question 37) Colon or rectal Prostate Colon or rectal Colon or rectal Prostate Colon or rectal </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>🗌 No</td> <td>,</td> <td></td>								🗌 No	,	
Have you ever had cervical cancer screening? Yes No (go to question 35) Never heard of this (go to questi *collecting cells from cervix to test for cancer* If yes cervical cancer screening 3 YEARS AGO dup ou receive any treatment? Yes No (go to question 36) Never heard of this (go to question 37) Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Family History a a a b b b b b b b c 	34. (FOR WOMEN ONLY)									
□ cervical cancer screening 3+ YEARS AGO ↓ 34a. Did you receive any treatment? □ Yes … (specify) No 35. (FOR WOMEN ONLY) Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* Nammogram <2 YEARS AGO ↓ If yes *x-ray of breasts* Mammogram 2+ YEARS AGO ↓ If yes *x-ray of breasts* Banding and the following cancers? (Select as many as may apply.) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Breast Colon or rectal Prostate Cervical Colon or rectal Prostate Cervical Cancer (and cancer screening) Ovarian Pancreas In a construction I	lave you ever had cervical cancer scre	ening?			(go to que	estion 35)	Nev	ver hear	rd of this (g	o to questi
Yes (specify) No 35. (FOR WOMEN ONLY) Have you ever had breast cancer screening? Yes No (go to question 36) Never heard of this (go to question 46) (e.g. Mammogram) Yes Mammogram <2 YEARS AGO	collecting cells from cervix to test for	cancer*								
Yes			\checkmark							
35. (FOR WOMEN ONLY) Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* (a.g. Mammogram) *x-ray of breasts* (a.g. Mammogram) *x-ray of breasts* (b.g. Mammogram) *x-ray of breasts* (c.g. Mammogram) *x-ray of breasts* (b.g. Mammogram <2 YEARS AGO										
Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* Mammogram <2 YEARS AGO Mammogram 2+ YEARS AGO ↓ 35a.Did you receive any treatment? Yes(specify) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Mother Father Brother Sister Lung Mother Father I Compared Sister Lung Mother I Compared Sister Lung Mot			∐ Y∈	es		(specify)		No)	
Have you ever had breast cancer screening? (e.g. Mammogram) *x-ray of breasts* Mammogram <2 YEARS AGO Mammogram 2+ YEARS AGO ↓ 35a.Did you receive any treatment? Yes(specify) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Mother Father Brother Sister Lung Mother Father I Compared Sister Lung Mother I Compared Sister Lung Mot										
(e.g. Mammogram) *x-ray of breasts* Mammogram <2 YEARS AGO Mammogram 2+ YEARS AGO ↓ 35a.Did you receive any treatment? Yes(specify) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas	. ,						۰. ר			
x-ray of breasts Mammogram <2 YEARS AGO Mammogram 2+ YEARS AGO ↓ 35a.Did you receive any treatment? Yes(specify) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) <u>Mother</u> Father Brother Sister Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas		ning?			go to que	estion 36)	Nev	ver hear	rd of this (g	o to questi
Mammogram 2+ YEARS AGO ↓ 35a.Did you receive any treatment? Yes(specify) No Family History										
↓ 35a.Did you receive any treatment? ☐ Yes(specify) ☐ No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Image: Select as many as may apply. Imag	x-ray of breasts [*]									
Yes (specify) No Family History 36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Mother Father Sister Breast				ammograr	n z+ YEAI	KS AGU				
Yes										
Mother Father Brother Sister Lung Mother Father Brother Sister Breast Image:			25 - 5							
36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Image: Select as many as may apply.) Mother Father Breast Image: Select as many as may apply.) Colon or rectal Image: Select as many as may apply.) Prostate Image: Select as many as may apply.) Uterine (endometrial) Image: Select as many as may apply.) Ovarian Image: Select as many as may apply.)										
36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Mother Father Sister Breast Image: Colon or rectal Image: Cervical Image: Cervical Uterine (endometrial) Image: Cervical Image: Cervical Image: Cervical Pancreas Image: Cervical Image: Cervical Image: Cervical								🗌 No	,	
36. Have any of these relatives had the following cancers? (Select as many as may apply.) No family history of cancer (go to question 37) Mother Father Brother Sister Lung Mother Father Sister Breast Image: Colon or rectal Image: Cervical Image: Cervical Uterine (endometrial) Image: Cervical Image: Cervical Image: Cervical Pancreas Image: Cervical Image: Cervical Image: Cervical								🗌 No	1	
MotherFatherBrotherSisterLungIIIBreastIIColon or rectalIIProstateIICervicalIIUterine (endometrial)IIOvarianIIPancreasII	Family History							□ No	,	
No family history of cancer (go to question 37)MotherFatherBrotherSisterLungIIIBreastIIIColon or rectalIIIProstateIIICervicalIIIUterine (endometrial)IIIOvarianIIIPancreasIII	Family History							□ No		
MotherFatherBrotherSisterLungIIIBreastIIIColon or rectalIIIProstateIIICervicalIIIUterine (endometrial)IIIOvarianIIIPancreasIII		following	Y€	25		(specify)		No	,	
LungImage: Construction of the second of the se	36. Have any of these relatives had the		Ye	25		(specify)	_	No		
BreastImage: Color or rectalImage: Color or rectalProstateImage: Color or rectalProstateImage: Color or rectalCervicalImage: Color or rectalUterine (endometrial)Image: Color or rectalOvarianImage: Color or rectalPancreasImage: Color or rectal	36. Have any of these relatives had the	uestion 37)	Cancers?	(Select as r	many as r	(specify)	_	No		
Uterine (endometrial) Image: Constraint of the second se	36. Have any of these relatives had the No family history of cancer (go to q	uestion 37)	Cancers?	(Select as r	many as r	(specify)	_	No	,	
Uterine (endometrial) Image: Constraint of the second se	36. Have any of these relatives had the No family history of cancer (go to q Lung	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
Uterine (endometrial) Image: Constraint of the second se	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
Uterine (endometrial) Image: Constraint of the second se	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
Uterine (endometrial) Image: Constraint of the second se	 36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal 	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
Pancreas Pancreas	 36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate 	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial)	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
Uther/unknown (specify) I I I I I I I I I I I I I I I I I I I	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
	36. Have any of these relatives had the No family history of cancer (go to q	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian	uestion 37)	Cancers?	(Select as r	many as r	(specify)			,	
Other/unknown(specify)	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas	uestion 37)	Cancers?	(Select as r	many as r	(specify)				
	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian	uestion 37)	Cancers?	(Select as r	many as r	(specify)			,	
37. Have any of these relatives had the following conditions? (Select as many as may apply.)	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown(specify)	Westion 37)	Father	(Select as r	nany as n	(specify) nay apply.)				
37. Have any of these relatives had the following conditions? (Select as many as may apply.) No family history of the below conditions (go to question 38)	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown(specify) 87. Have any of these relatives had the	e following of	Father	(Select as r Brother	nany as n	(specify) nay apply.)				
No family history of the below conditions (go to question 38)	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown(specify) 87. Have any of these relatives had the	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				
No family history of the below conditions (go to question 38) Mother Father Brother Sister	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown (specify) 87. Have any of these relatives had the No family history of the below cond	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				
No family history of the below conditions (go to question 38)	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown (specify) 87. Have any of these relatives had the No family history of the below cond	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				
No family history of the below conditions (go to question 38) Mother Father Brother Sister	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown (specify) 87. Have any of these relatives had the No family history of the below cond Diabetes	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)			,	
Mo family history of the below conditions (go to question 38)MotherFatherBrotherDiabetesIIHypertension (high blood pressure)II	36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown(specify) 87. Have any of these relatives had the No family history of the below cond Diabetes Hypertension (high blood pressure)	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				
MotherFatherBrotherSisterDiabetesIIIHypertension (high blood pressure)IIIMyocardial infarction (heart attack)III	 36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown (specify) 87. Have any of these relatives had the No family history of the below cond Diabetes Hypertension (high blood pressure) Myocardial infarction (heart attack) 	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				
Mo family history of the below conditions (go to question 38) Mother Father Brother Sister Diabetes Image: Construction of the blood pressure Image: Construction of the blood pressure Image: Construction of the blood pressure	 36. Have any of these relatives had the No family history of cancer (go to q Lung Breast Colon or rectal Prostate Cervical Uterine (endometrial) Ovarian Pancreas Other/unknown (specify) 87. Have any of these relatives had the No family history of the below cond Diabetes Hypertension (high blood pressure) Myocardial infarction (heart attack) High cholesterol 	e following of the foll	Father Condition	(Select as r Brother S? (Select a S? (Select a S)	nany as n	(specify) nay apply.)				

Page 37 of 45

38. Have you sm	ioked 5 packs of in past, but quit	-		r more in s, current				(go to que	oction 20
\downarrow If smoked in p		-		urrently s	-			igo to que	511011 55
Quit <2 YEAF				unchity 5	more				
Quit 2+ YEAF									
↓			+						
38a. At each ag	ge: Average nun	nber of ci	garettes	per day					
		1	None	1-4	5-14	15-24	25-35	36-44	45+
Current									
<2 years ago									
Age < 15 years									
Age 15-19 year	ſS								
	rs (if applicable)								
	rs (if applicable)								
	rs (if applicable)								
	rs (if applicable)								
Age 60 to the p	present (<i>if applic</i>	able)							
\downarrow If drank in pa	st		If cu	urrently d	rink				
Quit <2 YEAF Quit 2+ YEAF	RS AGO								
	RS AGO		Ļ						
Quit 2+ YEAF ↓	RS AGO	al numbe	r of drin	ks (e.g., to	otal num	per of bot	ttles/can	is of	
Quit 2+ YEAF ↓ 40a. At each ti	RS AGO RS AGO me period: Usua f wine, shots of		r of drin		-	per of bot			
Quit 2+ YEAF ↓ 40a. At each ti	RS AGO RS AGO me period: Usua f wine, shots of None or less	liquor) 1-3	1 per	2-4 per	5-6	7-13 pe	er 14	+ per	
Quit 2+ YEAF ↓ 40a. At each ti	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	-		5-6 per		er 14		
Quit 2+ YEAF ↓ 40a. At each ti beer, glasses o	RS AGO RS AGO me period: Usua f wine, shots of None or less	liquor) 1-3	1 per	2-4 per	5-6	7-13 pe	er 14	+ per	
Quit 2+ YEAF	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	
Quit 2+ YEAF 40a. At each ti beer, glasses o Current <2 years ago	RS AGO RS AGO me period: Usua f wine, shots of None or less than 1	liquor) 1-3 per	1 per	2-4 per	5-6 per	7-13 pe	er 14 [.]	+ per	

BMJ Open

.

Page 6 of 12

						Freque	ncy *in t	he last 2 y	/ears*	
	1								were well)	
	Ever taken	IF yes →	Taken in the past 2 years'		1 day a month or less	2-3 days a month	One day a week	2-3 days a week	4-5 days a week	6+ day wee
Acetaminophen (e.g., Panadol, Paracetamol, Tylenol)	Yes No		🗌 Yes 🗌 N	0						
Aspirin (e.g., Anacin, Bufferin, Alka-Seltzer)	🗌 Yes 🗌 No		🗌 Yes 🗌 N	o						
Other anti- inflammatory (e.g., Ibuprofen, Diclofenac, Indocin, Naprosyn, Advil)	Yes No		Yes 🗌 N	0						
Anti-high blood pressure	Yes No		🗌 Yes 🗌 N	0						
Anti-diabetic (e.g., Metformin)	Yes No		🗌 Yes 🗌 N							
Anti-high cholesterol	Yes No		Yes N	0						
Multivitamin	🗌 Yes 🗌 No		Yes 🗌 N	o						
Folate only/vitamin B9 supplement	🗌 Yes 🗌 No		🗌 Yes 🗌 N	0						
Calcium only supplement	Yes No		🗌 Yes 🗌 N	0						
Vitamin D only supplement	Yes No		🗌 Yes 🗌 N	0						
Steroid	🗌 Yes 🗌 No		🗌 🗌 Yes 🗌 N	o						
Herbal supplements	Yes No		🗌 Yes 🗌 N	0						
🗌 Yes 📃 No (go to que								., ,	mpicillin cl	
 If yes 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but If taken in past Most recently stopped 	in) In)	her ant e last 2	years* (* FOR (es, currently t	aking [No	were well		npiclox (ai		oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but If taken in past Most recently stopped 	in) In) In) In) In Flace In the second se	her ant e last 2 D e TOTA	ibiotic(<i>years</i> * (* FOR (es, currently t L amount of ti	CASES US	E: When you No Ised any anti	were well	*)?			oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but If taken in past Most recently stopped 	in) In) In) In) In Flace In the second se	her ant e last 2	ibiotic(years* (* FOR (es, currently t	CASES US aking [me you u	E: When you No Ised any anti lays >2-4	were well	*)?	4 4+	- -	oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but If taken in past Most recently stopped 	in) In) In) In) In Flace In the second se	her ant e last 2 D e TOTA	ibiotic(years* (* FOR Yes, currently t AL amount of ti Less 8-15	CASES US aking [me you u	E: When you No Ised any anti lays >2-4 month	were well	*)?	4 4+	- -	oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but If taken in past Most recently stopped 	in) In) In) In) In Flace In the second se	her ant e last 2 D e TOTA	tibiotic(years* (*FOR (es, currently t Lamount of ti Less 8-15 than days 7	CASES US aking [me you u 16 c to 2	E: When you No Ised any anti lays >2-4 month	biotics: >4 s month to 2	*)?	4 4+	- -	oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but Yes, taken in past Most recently stopped Most recently stopped 3. At each period of your 	in) Fla Ot antibiotic * <i>in the</i> : stopped d <6 WEEKS AGC d 6+ WEEKS AGC <u>r life: Indicate th</u> N	her ant e last 2 D e TOTA	tibiotic(years* (*FOR (es, currently t Lamount of ti Less 8-15 than days 7	CASES US aking [me you u 16 c to 2	E: When you No Ised any anti lays >2-4 month	biotics: >4 s month to 2	*)?	4 4+	- -	oxacil
 2a. Select as many as ma Cipro tab (ciprofloxaci Amoxil (amoxicillin) 2b. Have you taken any a Yes, taken in past, but Yes, taken in past Yes, taken in past Most recently stopped Most recently stopped 3. At each period of your 	in) Fla Ot antibiotic * <i>in the</i> : stopped d <6 WEEKS AGC d 6+ WEEKS AGC <u>r life: Indicate th</u> N	her ant e last 2 D e TOTA	tibiotic(years* (*FOR (es, currently t Lamount of ti Less 8-15 than days 7	CASES US aking [me you u 16 c to 2	E: When you No Ised any anti lays >2-4 month	biotics: >4 s month to 2	*)?	4 4+	- -	oxacil

BMJ Open

1	44. Have you EVER taken an antiparasi Yes No (go to question 46)	tic/anthe	lmintic m	edicatior	ו?					
2	\downarrow If yes									
3	44a. Select as many as may apply:									
4	Zentel (albendazole)	in 🗌	Combant	rin (meb	endazole)	🗌 Ken	trax			
5 6	Other antiparasitic/anthelmintic			(specify)						
7	44b. Have you taken any antiparasitic/						SE : When y	ou were	well*) ?	
8	Yes, taken in past, but stopped		Yes, curr	ently taki	ng 🗌 No	0				
9	\downarrow If taken in past									
10	Most recently stopped <6 WEEKS A									
11	Most recently stopped 6+ WEEKS A	GO								
12 13	45. At each period of your life: Indicate	the TOT	AL amour	nt of time	you used a	any antipa	rasitic/anth	elmintics		_
14		None	Less	8-15	16 days	>2-4	>4	>2-4	4+	
15			than	days	to 2	months	months	years	years	
16			7		months		to 2			
17			days				years			
18	During the past 2 years				-					
19	Age < 19 years									-
20	Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>)									
21	Age 60 to the present (<i>if applicable</i>)									-
22	Age 60 to the present (1) applicable)]
23 24	46. Have you EVER taken an antimalari	al medica	ation?							
24 25	🗌 Yes 🗌 No (go to question 48)									
26	\downarrow If yes						_	_		
27	46a. Select as many as may apply:				-				her (e.g.,	
28	Artesunate/mefloquine (e.g., Arteq	· · =				-				amoquin)
29	Chloroquine (e.g., Aralen)			one/prog	uanil (e.g.,	Malanil, M	alarone)	Quinin	e	
30	Other antimalarial	(spe	city)							
31										
21	46b. Have you taken any antimalarial *	in the las	st 2 years	* (*FOR (CASES USE:	When you	were well*)?		
32	46b. Have you taken any antimalarial *		-		CASES USE:		were well*) ?		
32 33	\Box Yes, taken in past, but stopped \downarrow If taken in past		-				were well*)?		
32 33 34	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A 	.GO	-				were well*)?		
32 33 34 35	\Box Yes, taken in past, but stopped \downarrow If taken in past	.GO	-				were well*)?		
32 33 34 35 36	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 	GO GO	Yes, curr	ently taki	ng 🗌 No) ?		
32 33 34 35 36 37	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A 	GO GO	Yes, curr	ently taki	ng 🗌 No)? > 2-4	4+	I
32 33 34 35 36 37 38	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 	GO GO the TOT	Yes, curr AL amour	ently taki	ng 🗌 No	any antima	larial:		4+ years	
32 33 34 35 36 37 38 39	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 	GO GO the TOT	Yes, curr AL amour Less	ently taki nt of time 8-15	ng No 2 you used a 16 days	any antima	larial: >4	>2-4		
32 33 34 35 36 37 38 39 40	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 	GO GO the TOT	Yes, curr AL amour Less than	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months	>2-4		
32 33 34 35 36 37 38 39	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
32 33 34 35 36 37 38 39 40 41	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
32 33 34 35 36 37 38 39 40 41 42	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
32 33 34 35 36 37 38 39 40 41 42 43 44 45	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) 	GO GO the TOT	Yes, curre AL amour Less than 7	ently taki nt of time 8-15	ng No you used a 16 days to 2	any antima	larial: >4 months to 2	>2-4		
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) 	GO GO the TOT, None	Yes, curr AL amour Less than 7 days	ently taki at of time 8-15 days	e you used a 16 days to 2 months	any antima >2-4 months	larial: >4 months to 2 years	>2-4 years	years	
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) 	GO GO the TOT/ None	AL amour Less than 7 days ON IS FO	ently taki at of time 8-15 days	e you used a 16 days to 2 months	any antima >2-4 months	larial: >4 months to 2 years	>2-4 years	years	V <i>54)</i>
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) Reproductive History (<i>THE FOLLOWI</i>) 48. Age (years) your menstrual periods 	GO GO the TOTA None	AL amour Less than 7 days	ently taki at of time 8-15 days	e you used a 16 days to 2 months	any antima >2-4 months	larial: >4 months to 2 years Y; FOR MEI	>2-4 years	years	v 54)
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) Reproductive History (<i>THE FOLLOWI</i> 48. Age (years) your menstrual periods 49. Have your menstrual periods stopp 	GO GO the TOT/ None None	AL amour Less than 7 days ON IS FO	ently taking the second	ng No you used a 16 days to 2 months NPARTICIF * * If Rej	any antima >2-4 months PANTS ONL fused/Don	larial: >4 months to 2 years Y; FOR MEI	>2-4 years	years	V 54)
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) 48. Age (years) your menstrual periods 49. Have your menstrual periods stopp Yes 	GO GO the TOTA None	AL amour Less than 7 days ON IS FO	ently taking the second	e you used a 16 days to 2 months	any antima >2-4 months PANTS ONL fused/Don	larial: >4 months to 2 years Y; FOR MEI	>2-4 years	years	V 54)
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) Reproductive History (<i>THE FOLLOWI</i> 48. Age (years) your menstrual periods 49. Have your menstrual periods stopp 	GO GO e the TOT, None None None Not sure	AL amour Less than 7 days ON IS FO	ently taking the of time 8-15 days R WOME (years)'	ng No you used a 16 days to 2 months NPARTICIF * * If Rej	any antima >2-4 months PANTS ONL fused/Don	larial: >4 months to 2 years Y; FOR MEI	>2-4 years	years)
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) 48. Age (years) your menstrual periods 49. Have your menstrual periods stopp Yes No ↓ If yes 	GO GO the TOT/ None None None Nosection began?_ ed perma Not sure ears)*	AL amour Less than 7 days ON IS FO	ently taking to find the second secon	ng No you used a 16 days to 2 months <i>N</i> PARTICIF * * If Rej Don't Know	any antima >2-4 months PANTS ONL fused/Don	larial: >4 months to 2 years years Y; FOR MEI	>2-4 years	years QUESTIO	V <i>54)</i>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) 48. Age (years) your menstrual periods 49. Have your menstrual periods stoppe Yes No ↓ If yes 49a. Age period stopped (years) 	GO GO The TOTA None None None None Not Sure ears)* not inclu	AL amour Less than 7 days ON IS FO	nt of time 8-15 days days Refused/ Refused/ nt pregna	ng No you used a 16 days to 2 months NPARTICIF * * If Re, Don't Know ncy or thos	Any antima >2-4 months PANTS ONL fused/Don fused/Don v c, enter 999 se ending a	larial: >4 months to 2 years years Y; FOR MEI	>2-4 years	years QUESTIO	V 54)
 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 	 Yes, taken in past, but stopped ↓ If taken in past Most recently stopped <6 WEEKS A Most recently stopped 6+ WEEKS A 47. At each period of your life: Indicate During the past 2 years Age < 19 years Age 20-39 years (<i>if applicable</i>) Age 40-59 years (<i>if applicable</i>) Age 60 to the present (<i>if applicable</i>) 48. Age (years) your menstrual periods stopp Yes No ↓ If yes 49. Have you ever been pregnant? (Do Yes No ↓ If yes 	GO GO e the TOT, None None None None Not Sure ears)* not inclu Not sure	AL amour Less than 7 days ON IS FO	ently taking at of time 8-15 days days Refused/ Refused/ At pregna Refused/	ng No you used a 16 days to 2 months <i>N PARTICIP</i> * <i>* If Rej</i> Don't Know ncy or thos Don't Know	any antima >2-4 months pants onl fused/Don fused/Don v e enter 999 se ending a	larial: >4 months to 2 years years Y; FOR MEI	>2-4 years	years QUESTIO	v 54)

50a. Age at first pregnancy					BMJ	Open			Pa	age 8 of	12	Page 40
S0c. Age at birth of last child(years)* *if Refused/Don't Know, enter 999 S0d. Number of live births * *if Refused/Don't Know, enter 999 S0d. Number of live births * *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Average transplate pregnancies *if Refused/Don't Know, enter 999 S0d. Number of incomplete pregnancies *if Refused/Don't Know (go to question 52) S0d. Number of pregnancies *if Refused/Don't Know (go to question 52) S1d. For how long did you use these hormones (years)? <1 1 2 3 -4 5 -7	50a. Age at first pregnancy _	(years)	*	*lf	Refused/	Don't Kno	w, enter 9	99				
Soc. Age at birth of last child(years)***/f Refused/Don't Know, enter 999 Sod. Number of live births**/f Refused/Don't Know, enter 999 Sod. Number of live births**/f Refused/Don't Know, enter 999 Sod. Average bireastfeeding duration (months) 0 0 1-6 7-12 13.18 19-24 24.36 36+ Sog. Average time between births (years) 0 1-12 3.4 4-7 8+ years Soh. In what way/ways was your child/children delivered? (Select all that apply) Vaginal birth	50b. Age at birth of first chil	d (vea	rs)*	*If	Refused/	Don't Kno	w, enter 9	99				
50d. Number of live births* *'If Refused/Don't Know, enter 999 50e. Number of incomplete pregnancies* *'If Refused/Don't Know, enter 999 50f. Average breastfeeding duration (months) 0 1-6 7:12 13.18 19.24 24.36 36+ 50g. Average time between births (years) 1 1-2 3.4 4-7 3+ years 50h. In what way/ways was your child/children delivered? (Select all that apply.) Vaginal birth C-section 51 Have you EVER used replacement sek hormones (e.g., estrogen, progesterone)? Yes, used in past, but stopped Yes, currently use No (go to question 52.) Refused/Don't Know (go to question 52.) 51 Free of hormone use donest recently? Oral Patch Vaginal Other				-	-							
50e. Number of incomplete pregnancies* *if Refused/Don't Know, enter 999 50f. Average breastfeeding duration (months) 0 1-6 7-12 13-18 19-24 24-36 36+ 50g. Average time between births (years) 1 1-2 34 44-7 *********************************			5)	-								
507. Average breastfeeding duration (months) 0 1-6 7-12 13-18 19-24 24-36 36+ 50g. Average time between births (years) <1				-	-							
S0g. Average time between births (years) <1	50e. Number of incomplete	pregnancies	*	*If	Refused/	Don't Kno	w, enter 9	99				
50h. In what way/ways was your child/children delivered? (Select all that apply.) Vaginal birth C-section 51. Have you EVER used replacement sex hormones (e.g., estrogen, progesterone)? 'es, used in past, but stopped 'es, currently use No (go to question 52) Refused/Don't Know (go to question 52) fi used in past, but stopped 'es, currently use Stopped -2 YEARS AGO Stopped -2 YEARS AGO - For how long did you use these hormones (years)? <1 2 3.4 5-7 8+	50f. Average breastfeeding of	duration (mont	hs) 🗌 C] 1-6	7-12	13-18 🗌	19-24] 24-36 [36+		
51. Have you EVER used replacement sex hormones (e.g., estrogen, progesterone)? \[\begin{tabular}{lllllllllllllllllllllllllllllllllll	50g. Average time between	births (years)	<1]1-2	3-4 4	-7 🗌 8+	- years				
51. Have you EVER used replacement sex hormones (e.g., estrogen, progesterone)? \[\extrmsold in past, but stopped \] Yes, currently use \] No (go to question 52) \] Refused/Don't Know (go to question 52) \] \[\extrmsold in past, but stopped \] Yes, currently use \] \[No (go to question 52) \] \[Stopped 2 YEARS AGO \] \[If currently use \] \[Stopped 2 YEARS AGO \] \[If currently use \] \[Stopped 2 YEARS AGO \] \[If currently use \] \[Stopped 2 YEARS AGO \] \[If currently use \] \[Stopped 2 YEARS AGO \] \[If currently use \] \[Stopped 2 YEARS AGO \] \[Oral \] \[Stopped 2 YEARS AGO \] \[Stopped 2 YEARS AGO \] \[Stopped 2 YEARS AGO \] \[Stopped 2 YEARS AGO \] \[Stopped 2 YEARS AGO \] \[Yes, currently use \] No (go to question 54) \] Refused/Don't Know (go to question 54) \] \[Stopped 2 YEARS AGO \] \[Yes, sued in past, but stopped \] Yes, currently use \] No (go to question 54) \] Refused/Don't Know (go to question 54) \] \[Stopped 2 YEARS AGO \] \[Stopped 2 YEARS AGO \] \[Sponge \] Diaphragm/cervical cap \] \[Tubal ligation (tubes tied) \] Foan or jelh \] \[None \] Coral contraceptive well Was forms of contraception have you used? (Select as many as may apply.) \] </td <td>50h. In what way/ways was</td> <td>vour child/child</td> <td>dren deli</td> <td>vere</td> <td>d? (Select</td> <td>all that a</td> <td>v 🗌 (.vlad</td> <td>Vaginal bi</td> <td>rth 🗌 C</td> <td>-section</td> <td></td> <td></td>	50h. In what way/ways was	vour child/child	dren deli	vere	d? (Select	all that a	v 🗌 (.vlad	Vaginal bi	rth 🗌 C	-section		
□ Yes, used in past, but stopped □ Yes, currently use □ No (go to question 52) □ Refused/Don't Know (go to question 52) □ Stopped 22 YEARS AGO □ If currently use □ If currently use □ Stopped 22 YEARS AGO □ If currently use □ Stopped 24 YEARS AGO □ Stopped 24 YEARS AGO □ If currently use □ If currently use S1a. For how long did you use these hormones (years)? □ I □ 2 □ 3-4 □ 5-7 □ 8+ S1b. Type of hormone used most recently? □ Patch □ Vaginal □ Other					-			0				
Yes, used in past, but stopped Yes, currently use No (go to question 54) Refused/Don't Know (go to question 54) Stopped <2 YEARS AGO Stopped 24 YEARS AGO Stopped 25 Guide 26 Contraceptive Songe Diaphragm/cervical cap Tubal ligation (tubes tied) Foam or jelk Intrauterine device Condom Vasectomy Implant Injection Other Refused/Don't Know (the contraceptive	 ↓ if used in past ☐ Stopped <2 YEARS AGO ☐ Stopped 2+ YEARS AGO ↓ 51a. For how long did you us 51b. Type of hormone used 	se these hormo most recently?	rently us ones (yea	ie ars)?	☐ <1 Patch	1	2	3-	4 🔲 5-'	7 🗌 8+	(go to qu	uestion 52)
Stopped 2+ YEARS AGO 53. (FOR CASES ADD: When you were well) What forms of contraception have you used? (Select as many as may apply.) None Oral contraceptive Sponge Diaphragm/cervical cap Tubal ligation (tubes tied) Foam or jelly Intrauterine device Condom Vasectomy Implant Injection Other Refused/Don't Kno Nutrition History Stopped 2+ times a month 1-3 times a month 1 time a week 2 or more times a day 54. (FOR CASES ADD: When you were well) How often did/do you eat meals at a restaurant and/or buka in the last year? 1 time a day 2 or more times a day 55. (FOR CASES ADD: When you were well) Kindly recall your food habits during the last year when filling this portion. (Select as many as may apply.) See photographic guide for specific foods and medium portion size. *S=Small, M=Medium, L=Large* Beverages and Other Drinks (Page 2 of photographic guide) Never Less 1-3 1 times a					·				-	-	-	uestion 54)
53. (FOR CASES ADD: When you were well) What forms of contraception have you used? (Select as many as may apply.) None Oral contraceptive Sponge Diaphragm/cervical cap Tubal ligation (tubes tied) Foam or jelly Intrauterine device Condom Vasectomy Implant Injection Other Refused/Don't Kno Nutrition History												
□ 2-4 times a week □ 1 time a day □ 2 or more times a day 55. (FOR CASES ADD: When you were well) Kindly recall your food habits during the last year when filling this portion. (Select as many as may apply.) See photographic guide for specific foods and medium portion size. *S=Small, M=Medium, L=Large* Beverages and Other Drinks (Page 2 of photographic guide) Serving Serving Never Less 1-3 1 time 2-4 5-6 1 2 or more times a day Soft drinks e.g coca cola 35cl Never Less 1-3 1 time 2-4 5-6 1 2 or Natural fruit juice 35cl N L Note Never Less 1-3 1 times a a a times a a times a a a a a a a a a	Nutrition History			-								Don't Know
many as may apply.) See photographic guide for specific foods and medium portion size. *S=Small, M=Medium, L=Large*Beverages and Other Drinks (Page 2 of photographic guide)Medium servingServingNever SLess than once a month1 time a month2-4 times a a week5-6 times 	Never	less than onc	e a mon			1-3 times	a month	11	ime a we	ek	-	
Beverages and Other Drinks (Page 2 of photographic guide) Medium serving Serving Never Less 1-3 1 time 2-4 5-6 1 2 or more a a more times Soft drinks e.g coca cola 35cl Image: serving and times I	55. (FOR CASES ADD: When	you were well)	Kindly r	ecall	your food	l habits <i>dι</i>	ring the l	ast year w	hen fillin	g this por	tion. (Sel	ect as
Medium servingServingNever SLess than once a month1-3 times a month1 time times a week2-4 times a week5-6 times a a week1 time a a a week1 time times a a week5-6 times a a a a a a day1 time more times a a week1 time times a a week5-6 times time a a a a day1 time more times a a week1 time times a a week5-6 times times a a day1 time more times a a a week2 or times a a a week2 or times times a a week1 times times a a week1 time times a a week1 time times times a a week1 time times times a a week2 or times times a a a week1 time times times a a week1 time times times a a week2 or times times a a a day2 or times times a daySoft drinks e.g coca cola35cl11	many as may apply.) See ph	otographic guid	de for sp	ecifi	c foods ar	nd mediur	n portion	size. *S=	Small, M=	Medium	, L=Large	*
Medium servingServingNever SLess than once a month1-3 times a month1 time times a week2-4 times a week5-6 times a a week1 time a a a week1 time times a a week5-6 times a a a a a a day1 time more times a a week1 time times a a week5-6 times time a a a a day1 time more times a a week1 time times a a week5-6 times times a a day1 time more times a a a week2 or times a a a week2 or times times a a week1 times times a a week1 time times a a week1 time times times a a week1 time times times a a week2 or times times a a a week1 time times times a a week1 time times times a a week2 or times times a a a day2 or times times a daySoft drinks e.g coca cola35cl11	Beverages and Other Drinks	s (Page 2 of pho	otograpl	nic gu	iide)							
Soft drinks e.g coca cola35clonce a montha monthweeka montha weeka daya day a daySoft drinks e.g coca cola35cl<		Medium	Servii	ng	Never	Less	1-3	1 time	2-4	5-6	1	2 or
Image: section of the section of th		serving	S N	1 L								
Soft drinks e.g coca cola35clImage: solar so								week				
Natural fruit juice35cl35cl35clJuice blends e.g 5 alive35cl35cl35clMilk and milk products½ litre35cl35clKunu, sobo½ litre35cl35clKunu, sobo½ litre35cl35clCoffee35cl35cl35clTea35cl35cl35clWater50 cl35cl35cl						month	month		WEEK	WEEK	uay	auay
Juice blends e.g 5 alive35clImage: second sec	Soft drinks e.g coca cola	35cl										
e.g yoghurt Image: Constraint of the state												
Kunu, sobo ½ litre Image: Constraint of the second	Natural fruit juice	35cl										
Coffee 35cl Image: Constraint of the second	Natural fruit juice Juice blends e.g 5 alive	35cl 35cl										
Tea 35cl Image: Constraint of the second se	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt	35cl 35cl ½ litre										
Water 50 cl	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo	35cl 35cl ½ litre ½ litre										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee	35cl 35cl ½ litre ½ litre 35cl										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee Tea	35cl 35cl ½ litre ½ litre 35cl 35cl										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee Tea Water	35cl 35cl ½ litre ½ litre 35cl 35cl										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee Tea Water	35cl 35cl ½ litre ½ litre 35cl 35cl										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee Tea Water	35cl 35cl ½ litre ½ litre 35cl 35cl										
	Natural fruit juice Juice blends e.g 5 alive Milk and milk products e.g yoghurt Kunu, sobo Coffee Tea Water	35cl 35cl ½ litre ½ litre 35cl 35cl										

Meats, Fish, Chicken, and Eggs (Pages 1 and 3 of photographic guide)

	Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 or
	serving					than	times	time	times	times	time	more
						once a	а	а	а	а	а	times
						month	month	week	week	week	day	a day
		S	Μ	L								
Fried beef/veal/pork/lamb/goat	1 cut											
Fried fish	1 cut											
Fried chicken	1 cut											
Fried egg	1 egg											
Boiled beef/veal/	1 cut											
pork/lamb/goat												
Boiled fish/chicken/egg	1 cut/											
	1 egg											
Smoked beef/veal/pork/lamb/goat	1 cut											
Smoked fish	1 cut											
Grilled/roasted beef/veal/pork/	1 cut or 3											
lamb/goat	sticks											
e.g. suya, asun, kilishi, ponmo												
Grilled/roasted fish	1 cut											
Offal	1 cut											
e.g. abodi, shaki, ifun												
Bushmeat/wildmeat	1 cut											
Snails	1 snail											
Other												
nacks (Pages 1 and 4 of photographic	c guide)											
	Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 or
	serving	S	Μ	L		than	times	time	times	times	time	more
	_					once a	а	а	а	а	а	times
						month	month	week	week	week	day	a day
Fried snacks e.g. puff puff, chin	½ cup					0						
chin, donut, buns, plantain chip	1 modium											
Baked Snacks	1 medium	1	1						1			

31					month	month	week	week	week	day	a day
32	Fried snacks e.g. puff puff, chin	½ cup			6						
33	chin, donut, buns, plantain chip										
34	Baked Snacks	1 medium			1						
35	e.g pie, biscuit, cake	package									
36	Roasted /popped Snacks	½ cup									
37	e.g. popcorn, corn										
38 39	Nuts	½ cup									
39 40	e.g. kola nut, gancina kola, walnut,										
40 41	cashew nut, tiger nut										
41	Other										
14											

Grains, Cereals, and Products (Pages 1 and 5 of photographic guide)

			<u> </u>	чр	<u></u>								
44		Medium	Se	rving	3	Never	Less	1-3	1	2-4	5-6	1	2 or
45		serving	ļ			ļ	than	times	time	times	times a	time	more
46			ļ			ļ	once a	а	а	а	week	а	times
47 49							month	month	week	week		day	a day
48 49			S	М	L								
49 50	Fermented milled cereals	1 cup or 1]										
50 51	e.g. pap, eko	wrap (eko)											
52	Boiled cereals	1 cup cooked]										
53	e.g maize, rice												
55 54	Whole meal product	1 cup or 1]										
55	e.g wheat, maize, rice	wrap											
56	Baked cereal products e.g bread	1 loaf (N100)]										
57	Idomine, spaghetti, pasta, noodles	1 cup cooked											
58	Other												
50		·	· · · ·	L		l	<u> </u>		<u> </u>	<u> </u>	· · · · · ·	·	

59 60

BMJ Open

Legumes and Products	(Pages 1 6 and 10 of	nhotogranhic guide)
Ecguines and Froduces	(1 uges 1, 0, und 10 01	photographic galacy

	Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 or
	serving					than	times	time	times	times	time	more
						once a	а	а	а	а	а	times
						month	month	week	week	week	day	a day
		S	М	L								
Boiled beans e.g ewa riro, moin moin, groundnut	1 cup cooked											
	or											
	1 wrap											
Fried legume product e.g akara	5 balls											
Soy product e.g cheese, milk	1 cup											
Other												

Roots/Tubers and Products (Page 7 of photographic guide)

15	Roots/ Tubers and Products (Page 7	or photogra	pine 8	suiue									
15 16		Medium	Serv	ving		Never	Less	1-3	1 time	2-4	5-6	1	2 or
16 17		serving					than	times	а	times	times	time	more
17							once a	а	week	а	а	а	times
10		$\mathbf{O}_{\mathbf{A}}$					month	month		week	week	day	a day
20			S	М	L								
20	Boiled tubers e.g. yam, cocoyam,	1 cup or 1											
22	potatoes	wrap											
23	Cassava products	1 wrap											
24	e.g garri. eba, fufu												
25	Fried product	5 slices											
26	e.g fried yam, potatoes, cocoyam				5								
27	Other												

Fruits/ Vegetables and Products (Pages 1, 8, and 10 of photographic guide)

	Medium	Ser	ving		Never	Less	1-3	1	2-4	5-6	1	2 or
	serving					than	times	time	times	times	time	more
						once a	а	а	а	а	а	times
						month	month	week	week	week	day	a day
		S	Μ	L								
Whole fruit	1 fruit					4						
e.g orange, mango, banana,	(medium)											
agbalumo, breadfruit	· /											
Processed fruit	1 cup											
Fried plantain	1 fruit											
	(medium)											
Grilled/roasted plantain e.g. Boli	1 fruit											
	(medium)											
Leafy vegetables	½ plate											
e.g pumpkin, amaranth, worowo,												
ewuro, spinach												
Other vegetables	½ cup											
e.g okra, onion, tomato, garden												
egg, cucumber, carrot, pepper												
Other												
						•	•			•		

Mushrooms and Products (Page 1 of photographic guide)

52		Medium	Serv	/ing		Never	Less	1-3	1	2-4	5-6	1	2 or
53		serving	S	Μ	L		than	times	time	times	times	time	more
54							once a	а	а	а	а	а	times
55							month	month	week	week	week	day	a day
56	Store bought mushrooms	1 cup											
57	Wild mushrooms	1 cup											
58	Other												
59													

		Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 0
		serving	S	M	L		than once a	times a	time a	times a	times a	time a	mo tin
Common Salt		1 toppoor	-				month	month	week	week	week	day	ас
Fermented seaso	ning agent	1 teaspoon 1 wrap	<u> </u>					+					├──
e.g Iru, ogiri	Shing agent	тмар											
Honey		1 teaspoon											
White sugar		5 cubes or											
white Sugar		1 teaspoon											
Artificial sweeter	hers	1/2											
e.g saccharin		teaspoon											
Oils		1											
e.g palm oil, vege	etable oil.	- tablespoon											
groundnut oil													
Other seasoning	s	1											
e.g ground dried		tablespoon											
fish, ogbonno, dr	•												
Other			-					1				1	
58. How long does	s it take your fami	ily to go throug	gh a	50 cl	cont	ainer of o	cooking oi	il?	(we	eks)			
Physical History										pushing	a vacuun	n cleane	r,
59. <u>CURRENTLY</u> , d carrying light load	s, walking briskly))? 🗌 Yes, limit	ed a	little	e [Yes, lin	nited a lot		a table,] No	pushing	a vacuun	n cleane	r,
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions	s, walking briskly) 5 60 and 61 are st	? Yes, limit	ed a	little y rela	e [ated]Yes, lim to your v	nited a lot work*	Ē] No	_			
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> breathing, heart ra continuously?	s, walking briskly) 5 60 and 61 are st DD: When you we ate, or sweating (? Yes, limit rictly about ac re well) Does/o ex. carrying or go to question (ed a tivit did y liftir 61)	y rela y rela y our N ng he	e [nted WOR avy l]Yes, lim to your v K require oads, dig you do tl	nited a lot vork * e any vigor ging or co	rous inten] No isity acti n work, (vity that etc) for a	caused i at least 10	ncrease 0 minut	s in es
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> breathing, heart ra continuously?	s, walking briskly) 5 60 and 61 are st 5 D: When you we ate, or sweating (☐ Yes ☐ No (g ↓ If yes 60a. In a typical w ☐ 1 day	P? Yes, limit re well) Does/o ex. carrying or to question o veek, on how n 3-4 days	ed a tivit did y liftir 61) nany	y relation y relation of the second s	e [nted WOR avy l avy l add 3 day	Yes, lim to your v K require oads, dig you do tl ys [hited a lot work* any vigor ging or co hese vigor 5+ days	rous inten instruction rous inten] No Isity acti n work, sity activ	vity that etc) for a vities as	caused i at least 10 part of yo	ncrease 0 minut our wor	s in es
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> breathing, heart ra continuously?	s, walking briskly) 5 60 and 61 are st 5 0D: When you we ate, or sweating (☐ Yes ☐ No (g ↓ If yes 60a. In a typical w ☐ 1 day 60b. In a typical d	P? Yes, limit rictly about ac re well) Does/ ex. carrying or to question of veek, on how n 3-4 days lay, for how lor	ed a tivit did y liftir 61) nany [ng di	y relations of the second seco	e [ated WOR avy la s did 3 day u do	Yes, lim to your v K require oads, dig you do tl ys [hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte	rous inten instruction rous inten] No sity acti n work, sity acti- vities as	vity that etc) for a vities as part of y	caused i at least 10 part of yo	ncrease 0 minut our wor	s in es
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> breathing, heart ra continuously?	s, walking briskly) 5 60 and 61 are st 5 0 : When you we ate, or sweating (☐ Yes ☐ No (g ↓ If yes 60a. In a typical w ☐ 1 day 60b. In a typical d ☐ 10-29 minutes	P? Yes, limit rictly about ac re well) Does/o ex. carrying or go to question o veek, on how n 3-4 days lay, for how lor 5 30	ed a tivit did y liftir 61) nany [ng di 0-59	days days days days dyou minu	e [ated WOR avy la s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys [hited a lot work* e any vigor ging or co hese vigor 5+ days orous inte 1 hour	rous inten instruction rous inten sensity acti] No sity acti n work, o sity activ vities as] 1.1 – 2	vity that etc) for a vities as part of y hours	caused i at least 10 part of yo	ncrease 0 minut our wor	s in es
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> breathing, heart ra continuously?	s, walking briskly) 5 60 and 61 are st 5 0D: When you we ate, or sweating (☐ Yes ☐ No (g ↓ If yes 60a. In a typical w ☐ 1 day 60b. In a typical d	P? Yes, limit rictly about ac re well) Does/o ex. carrying or go to question o veek, on how n 3-4 days lay, for how lor 5 30	ed a tivit did y liftir 61) nany [ng di 0-59	y relations of the second seco	e [ated WOR avy la s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys [hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte	rous inten instruction rous inten sensity acti] No sity acti n work, sity acti- vities as	vity that etc) for a vities as part of y hours	caused i at least 10 part of yo	ncrease 0 minut our wor	s in es
59. <u>CURRENTLY</u> , d carrying light load * <i>NOTE: Questions</i> 50. (<i>FOR CASES AL</i> preathing, heart ra continuously?	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours	P? Yes, limit rictly about ac re well) Does/ ex. carrying or to question of veek, on how n 3-4 days lay, for how lor 5 33	ed a tivit did y liftir 61) nany [ng di 0-59 1 – !	days days 2- d you minu 5 hou	e [mted WOR avy l 3 day 3 day 1 do 1 tes ites	Yes, lim to your v K require oads, dig you do tl ys these vig [hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7	rous inten onstruction rous inten ensity acti hours] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou	vity that etc) for a vities as part of y hours rs	caused i at least 10 part of yo your wor	ncrease 0 minut our wor k?	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 60. (FOR CASES AL breathing, heart ra continuously? 61. (FOR CASES AL oads, gardening,	s, walking briskly) 5 60 and 61 are st 2D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours 2D: When you we etc) for at least 10 Yes No (g	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor s 36 yee well) Does/a as	ed a tivit did y liftir 61) nany [ng di 0-59 1 – 5 1 – 5 did y inuo	little y rela rour \ ng he 2- d you minu 5 hou	e [nted WOR avy l d d d d d v tes wOR WOR	Yes, lim to your v K require oads, dig you do tl ys these vig [hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7	rous inten onstruction rous inten ensity acti hours] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou	vity that etc) for a vities as part of y hours rs	caused i at least 10 part of yo your wor	ncrease 0 minut our wor k?	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 60. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 Yes No (g ↓ If yes	P? Yes, limit rictly about ac re well) Does/ ex. carrying or go to question of veek, on how n 3-4 days lay, for how lor s 33 re well) Does/ Does/ Dominutes cont go to question of to question of	ed a tivit did y liftir 61) nany [ng di 0-59 1 – ! did y inuo 62)	little y rela our \ ng he days 2- d you minu 5 hou vour \ vour \	e [nted WOR avy li 3 day u do - utes rrs WOR	Yes, lim to your v K require oads, dig you do tl ys these vig L K require	hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod	rous inten onstruction rous inten ensity acti hours erate inte] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex	caused i at least 10 part of yo your wor	ncrease 0 minut our wor k? ;, carryir	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 60. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 ↓ If yes 61a. In a typical w	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac veek, on how n 3-4 days lay, for how lors s 30 re well) Does/a on how n 3-4 days lay, for how lors s 30 c 31 re well) Does/a o to question a yeek, on how n yeek, on how n	ed a tivit did y liftir 61) nany [nany 1 – 5 1 – 5 1 – 5 1 – 5 2 0 did y inuo 62) nany	little y rela our \ ng he days 2- d you minu 5 hou vour \ uusly?	e [mated WOR avy li s did do u do u do u tes urs WOR y s did	Yes, lim to your v K require oads, dig you do tl ys K require you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode	rous inten onstruction rous inten ensity acti hours erate inte erate inte] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex	caused i at least 10 part of yo your wor	ncrease 0 minut our wor k? ;, carryir	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 60. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 Yes No (g ↓ If yes	P? Yes, limit rictly about ac re well) Does/ ex. carrying or go to question of veek, on how n 3-4 days lay, for how lor s 33 re well) Does/ Does/ Dominutes cont go to question of to question of	ed a tivit did y liftir 61) nany [nany 1 – 5 1 – 5 1 – 5 1 – 5 2 0 did y inuo 62) nany	little y rela our \ ng he days 2- d you minu 5 hou vour \ vour \	e [mated WOR avy li s did do u do u do u tes urs WOR y s did	Yes, lim to your v K require oads, dig you do tl ys K require you do tl	hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod	rous inten onstruction rous inten ensity acti hours erate inte erate inte] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex	caused i at least 10 part of yo your wor	ncrease 0 minut our wor k? ;, carryir	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 ↓ If yes 61a. In a typical w	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question a yeek, on how n 3-4 days lay, for how lor s 30 yeek on how n 3-4 days lay, for how lor s 30 yeek on how n yeek, on how n 30 yeek, on how n 3-4 days a a day a a day a a day b a day	ed a tivit did y liftir 61) nany [0-59 1 – ! did y inuo 62) nany [little y rela our \ ng he days 2- d you minu cour \ cour \ vously?	e [nted WOR avy l avy l	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode hese mode	rous inten onstruction rous inten ensity acti hours erate inte erate inte] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity activ nsity activ	vity that etc) for a vities as part of y hours rs tivity (ex	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day	P? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question a week, on how n 3-4 days lay, for how lors 30 pre well) Does/a ay, for how lors 30 pre well) Does/a ay, for how lors ay by a b ay, for how lors by a b b b c b c b c b c b c b c b c b c b c b c b c b c b c b c b c b </td <td>ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [ng di</td> <td>little y rela our \ ng he days 2- d you minu cour \ cour \ vously?</td> <td>e [ated WOR avy li avy li add add add add add add add ad</td> <td>Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl</td> <td>hited a lot vork* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode hese mode</td> <td>rous inten onstruction rous inten ensity acti hours erate inte erate inte</td> <td>] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity activ nsity activ</td> <td>vity that etc) for a vities as part of y hours rs tivity (ex tivities as</td> <td>caused i at least 10 part of yo your wor walking s part of f</td> <td>ncrease 0 minut our wor k? ;, carryir your wo</td> <td>s in es k?</td>	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [ng di	little y rela our \ ng he days 2- d you minu cour \ cour \ vously?	e [ated WOR avy li avy li add add add add add add add ad	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot vork * any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode hese mode	rous inten onstruction rous inten ensity acti hours erate inte erate inte] No sity acti n work, o sity activ vities as] 1.1 – 2] 7+ hou ensity activ nsity activ	vity that etc) for a vities as part of y hours rs tivity (ex tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes 2.1 – 3 hours D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day 61b. In a typical d	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor go to question ac go to question ac yeek, on how n 3.4 days lay, for how lor go to question ac yeek, on how n 3.4 days lay, for how lor 3-4 days lay, for how lor 3-3 a	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [nany [nany]	little y rela our \ ng he days 2- d you minu 5 hou vour \ uusly? days 2- d you	e [mated WOR avy l s did 3 day u do utes WOR s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode 5+ days oderate in	rous inten instruction rous inten ensity acti hours erate inte erate inte tensity ac] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou ensity act nsity act	vity that etc) for a vities as part of y hours rs tivity (ex tivities as tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day 61b. In a typical d 10-29 minutes	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor go to question ac go to question ac yeek, on how n 3.4 days lay, for how lor go to question ac yeek, on how n 3.4 days lay, for how lor 3-4 days lay, for how lor 3-3 a	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [nany [nany]	little y rela our \ ng he days 2- d you minu cays 2- d you vour \ cays 2- d you minu	e [mated WOR avy l s did 3 day u do utes WOR s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode 5+ days oderate in 1 hour	rous inten instruction rous inten ensity acti hours erate inte erate inte tensity ac] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou ensity act nsity act nsity act	vity that etc) for a vities as part of y hours rs tivity (ex tivities as tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day 61b. In a typical d 10-29 minutes	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor go to question ac go to question ac yeek, on how n 3.4 days lay, for how lor go to question ac yeek, on how n 3.4 days lay, for how lor 3-4 days lay, for how lor 3-3 a	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [nany [nany]	little y rela our \ ng he days 2- d you minu cays 2- d you vour \ cays 2- d you minu	e [mated WOR avy l s did 3 day u do utes WOR s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode 5+ days oderate in 1 hour	rous inten instruction rous inten ensity acti hours erate inte erate inte tensity ac] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou ensity act nsity act nsity act	vity that etc) for a vities as part of y hours rs tivity (ex tivities as tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day 61b. In a typical d 10-29 minutes	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor go to question ac go to question ac yeek, on how n 3.4 days lay, for how lor go to question ac yeek, on how n 3.4 days lay, for how lor 3-4 days lay, for how lor 3-3 a	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [nany [nany]	little y rela our \ ng he days 2- d you minu cays 2- d you vour \ cays 2- d you minu	e [mated WOR avy l s did 3 day u do utes WOR s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode 5+ days oderate in 1 hour	rous inten instruction rous inten ensity acti hours erate inte erate inte tensity ac] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou ensity act nsity act nsity act	vity that etc) for a vities as part of y hours rs tivity (ex tivities as tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?
59. <u>CURRENTLY</u> , d carrying light load *NOTE: Questions 50. (FOR CASES AL preathing, heart ra continuously? 51. (FOR CASES AL oads, gardening,	s, walking briskly) 60 and 61 are st D: When you we ate, or sweating (Yes No (g ↓ If yes 60a. In a typical w 1 day 60b. In a typical d 10-29 minutes D: When you we etc) for at least 10 Yes No (g ↓ If yes 61a. In a typical w 1 day 61b. In a typical d 10-29 minutes	? Yes, limit rictly about ac re well) Does/a ex. carrying or go to question ac week, on how n 3-4 days lay, for how lor go to question ac go to question ac yeek, on how n 3.4 days lay, for how lor go to question ac yeek, on how n 3.4 days lay, for how lor 3-4 days lay, for how lor 3-3 a	ed a tivit did y liftir 61) nany [nany did y inuo 62) nany [nany [nany]	little y rela our \ ng he days 2- d you minu cays 2- d you vour \ cays 2- d you minu	e [mated WOR avy l s did 3 day u do utes WOR s did 3 day u do u do	Yes, lim to your v K require oads, dig you do tl ys these vig (K require you do tl you do tl	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod hese mode 5+ days oderate in 1 hour	rous inten instruction rous inten ensity acti hours erate inte erate inte tensity ac] No sity acti n work, sity activ vities as] 1.1 – 2] 7+ hou ensity act nsity act nsity act	vity that etc) for a vities as part of y hours rs tivity (ex tivities as tivities as	caused i at least 10 part of yo your wor walking s part of f	ncrease 0 minut our wor k? ;, carryir your wo	s in es k?

				BMJ Ope	า			Pag	ge 12 of 1	12
NOTE: Question 62 is stric	tlv about v	our activit	ies OUTSIE	E of work (includes	walkind	to and f	rom wo	ork)*	
·····	.,,			,,			, ,		,	
2. (FOR CASES ADD: When	you were	well) In the	last year,	what was y	our <u>aver</u>	age time	PER WE	EK spen	t at each	of the fo
ctivities OUTSIDE OF WOR								•		
	None	Less	10-29	30-59	1	1.1-2	2.1-3	3.1-5	5.1-7	7 or
		than 10	minutes	minutes	hour	hours	hours	hours	hours	more
		minutes								hours
Walking (to/from work or for exercise)										
Farming										
Collecting water										
Washing clothes (by hand))									
Cooking	·			1			1			t
Housecleaning				1						1
Lifting heavy objects										
Jogging (slower than 6				1						1
minutes/ km)										
Running (6 minutes/km or faster)		D,								
Bicycling										
Football										
Swimming										
Dancing			2							
Other vigorous activities (specify)			Ő,							
Other moderate activities										
(specify)										
3. (FOR CASES ADD: When	VOUNT	wall) What	ic huac voi	ur average t	imo DED	DAV coo	nt citting	or roci	ning in th	o lact w
10-29 minutes	30-59 m			iour		- 2 hours		, or reci	ining in ti	ie iast ye
2.1 - 3 hours	3.1 – 5			. – 7 hours						
		nours		. – 7 nours		ours				
Work & Home Exposures										
			·							
4. (FOR CASES ADD: When	-		· · · ·		-					the las
	Never	1-3 da	-	day per	2-4 da	-	5-6 days		/eryday	
		per m	onth w	eek	per w	eek	per wee	ĸ		
Burning waste (trash)										
Asbestos (from										
construction)										
Insecticides/pesticides										
Wastes from operating industries										

Cancer Awareness

65. Prior to today, had you ever heard of cancer?

Yes No (end of questionnaire)

 \downarrow If yes

52	65a. Prior to today, which cancers had you heard of? (Select as many as may apply.) Colon/rectum Breast Cervix
53	Prostate liver lung Other (specify)
54	65b. Do you know anyone who has had cancer? 🗌 Yes 📄 No
55	

65c. Prior to today, what things did you think affect a person's chance of deve	loping cancer? (Select as many as may apply.)
Do not know/Not sure Chance Depends on the cancer Gener	tics/family history 🔲 Body size

Lifestyle (e.g., smoking, alcohol)	Diet] Environment (e.g., livir	ng or working conditions)	Other	(specify)
------------------------------------	------	----------------------------	---------------------------	-------	-----------

	Item No	Recommendation	Pag No
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	4
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found	4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8,9
Objectives	3	State specific objectives, including any prespecified hypotheses	9
Methods			
Study design	4	Present key elements of study design early in the paper	10,11
Setting	5	 Describe the setting, locations, and relevant dates, including periods of 	10,11
		recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	10
	-	selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	10
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	11
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10,11
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	12,13
		(b) Describe any methods used to examine subgroups and interactions	12,13
		(c) Explain how missing data were addressed	13
		(<i>d</i>) If applicable, describe analytical methods taking account of	n/a
		sampling strategy	
		(<u>e</u>) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	13
		potentially eligible, examined for eligibility, confirmed eligible,	
		included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	13,14
		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	14,15

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	15,16
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(<i>b</i>) Report category boundaries when continuous variables were categorized	n/a
		(<i>c</i>) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	21
Limitations	19	Discuss limitations of the study, taking into account sources of	21-25
		potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	21-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	21-25
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.